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ABSTRACT OF THE DISSERTATION
Exosomal Survivin-T34A: A Novel, Potential Cancer Therapeutic
by
Jonathan Richard Aspe
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, June 2014
Dr. Nathan R. Wall, Chairperson
Pancreatic cancer is the fourth most common cause of cancer fatality in American
men and women with a less than 5% survival rate. Currently, if diagnosed early, surgical
resection remains the only viable cure. However, only 20% of pancreatic cancer patients
meet these criteria. It is therefore necessary to discover new therapies or therapeutic
combinations in order to impact significantly this deadly disease. The anti-metabolite
agent Gemcitabine is currently being employed to treat pancreatic cancer. While Gemcitabine has shown significant benefit in clinical applications, its ability to more than
modestly impact pancreatic cancer is limited. It has been speculated that combinatory
treatments using Gemcitabine could improve survival rates. Survivin, a member of the
inhibitor of apoptosis (IAP) protein family, is expressed in virtually all cancer cells, but
not detectable in most normal cells outside of development. Mutation of Survivin’s Threonine 34 to Alanine (Survivin-T34A) abolishes a phosphorylation site for p34cdc2-cyclin
B1 resulting in the initiation of the mitochondrial apoptotic pathway in cancer cells with
little to no direct effects on normal cells. The possibility that targeting Survivin in this
manner may provide a novel approach for selective cancer gene therapy has yet to be fully evaluated. We have recently described that cells generated to express a stable form of
the mutant protein, released this Survivin-T34A to the conditioned medium. When this
xiii

conditioned medium was collected and deposited on naive tumor cells, conditioned medium containing Survivin-T34A was as effective as chemotherapy in induction of tumor
cell apoptosis. When combined with other forms of genotoxic stress, Survivin-T34A potentiated their killing effects. We further determined that Survivin-T34A is trafficked by
microvesicles called exosomes, which are released into the conditioned media. We
showed strong evidence that exosomes containing Survivin-T34A elicited cellular death
and synergistically enhanced cellular death during combination with low doses of Gemcitabine and we propose that these findings may lead to novel modalities for cancer
therapies. This dissertation provides the rational for Survivin-T34A’s potential as a therapeutic. Next, we provide evidence that extracellular Survivin-T34A can elicit its antitumor effects on treated cells. Finally, I show that extracellular Survivin-T34A is found
in exosomes.
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CHAPTER ONE
SURVIVIN-T34A: MOLECULAR MECHANISM AND
THERAPEUTIC POTENTIAL

Jonathan R. Aspe and Nathan R. Wall

Center for Health Disparities & Molecular Medicine
Department of Basic Sciences/Division of Biochemistry & Microbiology
Loma Linda University
California 92350

Adapted from Aspe, J.R. and Wall, N.R. OncoTargets and Therapy (2010) 3, 247-25
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Abstract
The inhibitor of apoptosis (IAP) protein Survivin’s Threonine 34 to Alanine mutation abolishes a phosphorylation site for p34cdc2-cyclin B1 resulting in the initiation of
the mitochondrial apoptotic pathway in cancer cells yet has little known direct effects on
normal cells. The possibility that targeting Survivin in this way may provide a novel approach for selective cancer gene therapy has yet to be fully evaluated. Though a flurry of
work was undertaken in the late 90s and early 2000s, only minor advances on this mutant
have recently taken place. We recently described that cells generated to express a stable
form of the mutant protein, released this Survivin-T34A to the conditioned medium.
When this conditioned medium was collected and deposited on naive tumor cells, conditioned medium T34A was as effective as some chemotherapeutics in induction of tumor
cell apoptosis and when combined with other forms of genotoxic stressors, potentiated
their killing effects. In addition to determining the therapeutic dose and the duration of
drug therapy required at the disease site, a better understanding of other key factors is also important. These include knowledge of target cell populations, cell-surface receptors,
changes that occur in the target tissue at the molecular and cellular level with progression
of the disease, and the mechanism and site of therapeutic action.
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Introduction
Survivin is Important in Cancer
Apoptosis is a physiological cell suicide program that is critical for the development and maintenance of healthy tissues (Deveraux and Reed 1999). The evasion of
apoptosis, as identified by Hanahan and Weinberg, is a primary characteristic of human
cancer (Hanahan and Weinberg 2000) with proteins involved in its control of significant
biological interest as they could prove to be important targets for therapy development.
The inhibitor of apoptosis (IAP) family consists of proteins with proven ability to inhibit
apoptosis, although much of how this works mechanistically is still to be revealed. Survivin is an important IAP because its expression is among the most tumor specific of all
human gene products (Velculescu, Madden et al. 1999, Reed 2001). It has been classified
as a bifunctional protein as it can inhibit apoptosis and cell cycle (Li, Ambrosini et al.
1998). More specifically, Survivin’s promoter exhibits M phase inducible transactivation
and in HeLa cells, both Survivin protein and mRNA are upregulated at G2/M phase of the
cell cycle (Li, Ambrosini et al. 1998). Survivin expression is enhanced during embryonic
and fetal development, but not in terminally differentiated normal tissue (Li 2003). Its
expression has also been seen in virtually every type of human cancer (Andersen, Svane
et al. 2007), making Survivin an attractive protein in the study of cancer pathophysiology,
drug discovery and medical diagnosis. Our laboratory has recently shown that cancer
cells release Survivin into the extracellular space (Khan, Aspe et al. 2009) packaged in
small 50-150 nm vesicles called exosomes (Khan, Jutzy et al. 2010). This is significant as
it may reveal new mechanisms into how cancer cells communicate with one another and
how they affect the tumor microenvironment and we hope that this discovery may pro-
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vide other options for targeted therapy. However, this discovery begs for studies about
why and how Survivin is packaged within exosomes as well as how Survivin from exosomes is utilized by the recipient cells as well as what are the effects of exosomal
Survivin on normal human cells?
Survivin physically associates with and is phosphorylated on its 34 Threonine
(Thr34) by the cyclin-dependent kinase p34(cdc2)–cyclin B1 protein complex (O'Connor,
Grossman et al. 2000). Loss of Thr34 phosphorylation results in dissociation of the caspase-9-Survivin protein complex and caspase-dependent apoptosis (O'Connor, Grossman et
al. 2000, Mesri, Wall et al. 2001, Wall, O'Connor et al. 2003). Initially, Thr34 through
site-directed mutagenesis was changed to Ala (T34A) as a non-phosphorylated mimic of
Survivin (O'Connor, Grossman et al. 2000). When replication-deficient adenoviruses encoding this Survivin-T34A mutant were produced and used to infect cancer cell lines,
spontaneous apoptosis resulted. In contrast, the viability of normal human cells including
fibroblasts, endothelium and smooth muscle cells were unaffected (Mesri, Wall et al.
2001). In studies analyzing normal human oral mucosa, oral submucosa fibrosis and oral
squamous cell carcinomas (Zhou, Li et al. 2008), a gradation from no Survivin Thr34
phosphorylation in normal to significantly enhanced amounts of phosphorylated Survivin
Thr34 in the cancer tissues was recorded. Furthermore, phosphorylated Thr34 and
p34(cdc2) kinase expression was not detected in normal tissue samples but increased with
advancing stages in the cancer tissue samples (Zhou, Li et al. 2008). Agents that elevate
p34(cdc2) kinase activity during spindle checkpoint activation drive increased Survivin
expression and cancer cell viability (O'Connor, Wall et al. 2002) resulting in limited anticancer effects. Pharmacologic, genetic, or molecular ablation of p34(cdc2) kinase after
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microtubule stabilization resulted in apoptosis independent of p53, suppression of tumor
growth, and indefinite survival without toxicity in mice (O'Connor, Wall et al. 2002).
Taken together, the ablation of Survivin-dependent apoptosis inhibition could improve
the efficacy of many agents used to treat cancer.
One of the most daunting questions in any gene-based approach for cancer treatment is in the method of delivery. We have recently shown that Survivin exists in a novel
extracellular pool in tumor cells. Furthermore, we have constructed stable cell lines that
provide the extracellular pool with either wild-type Survivin or dominant-negative mutant
Survivin (T34A) (Khan, Aspe et al. 2009). Cancer cells grown in the conditioned medium
taken from wild-type Survivin expressing cells absorbed Survivin and experienced enhanced protection against genotoxic stress as well as exhibited an increased replicative
and invasive potential (Khan, Aspe et al. 2009). Alternatively, cancer cells grown in conditioned medium from T34A cells began to apoptose through a caspase-2- and caspase-9dependent pathway that was further enhanced by the addition of chemo- and radiotherapeutic modalities (Khan, Aspe et al. 2009), We believe that this extracellular SurvivinT34A could be used as a possible “White Knight” to Survivin’s “dark family”. The following sections detail T34A’s journey as a novel potential cancer therapeutic. The studies
above have already provided impetus for further studies on T34A, but there is still a lot
unknown. The advancement of future T34A studies may provide a more comprehensive
understanding of cancer and the potential of using T34A to battle it.

5

T34A Induces Apoptosis
What makes this Survivin-T34A mutant important as a potential therapeutic is
that little or no toxicity has resulted from its treatment in vitro or in vivo (Wall, O'Connor
et al. 2003, Yan, Thomas et al. 2006, Peng, Yang et al. 2008). T34A treated mice showed
significantly longer survival rates compared to control mice as well as had no pathologic
changes in major organs (Li, Zhao et al. 2009). More specifically, tumor cells treated in
vitro with T34A exhibited reduced cell survival that was associated with morphological
features of apoptosis (Mesri, Wall et al. 2001, Blanc-Brude, Mesri et al. 2003, McKay,
Bell et al. 2003, Fukuda and Pelus 2004, Liu, Brouha et al. 2004, Wang, Fukuda et al.
2004, Zhang, Mukherjee et al. 2005, Ma, Zheng et al. 2006, Yan, Thomas et al. 2006,
Peng, Yang et al. 2008, Zhang, Wang et al. 2008, Khan, Aspe et al. 2009, Shen, Liu et al.
2009, Xiao, Chen et al. 2010, Yu, Wang et al. 2010). Studies of mouse-xenographs treated with Survivin-T34A concluded with significant tumor size reduction and increased
animal survival rates (Blanc-Brude, Mesri et al. 2003, Yan, Thomas et al. 2006, Peng,
Yang et al. 2008, Li, Zhao et al. 2009, Yu, Wang et al. 2010) except in mice subcutaneously injected with the IGROV1 ovarian carcinoma cell line, where there were no
significant differences between T34A infected tumors and controls (McKay, Bell et al.
2003). These results may however be explained as IGROV1 cells do not express significant levels of endogenous Survivin and T34A, as shown in normal, Survivin nonexpressing cells, does not induce apoptosis (Mesri, Wall et al. 2001). It was not until
IGROV1 cells were infected with adenovirus-vector expressing caspase-3 (Ad-caspase-3)
or co-infected with Ad-caspase-3 & Ad-T34A that tumor size was reduced and survival
rates extended (McKay, Bell et al. 2003). It is of much interest that the adenoviruses used
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in these studies upregulated survivin mRNA, as shown by RT-PCR, and concomitantly
resulted in a half-fold reduction in another IAP, XIAP (McKay, Bell et al. 2003). Furthermore, in melanoma cells that have been engineered to express an inducible SurvivinT34A (Grossman, Kim et al. 2001), XIAP and the IAP Livin were cleaved upon T34A
induction (Liu, Brouha et al. 2004). These reductions may in part be responsible for the
more favorable outcomes observed in these studies. In contrast, it has been postulated
that the transfection of cells may affect endogenous levels of XIAP, but there was no effect on XIAP protein levels following transfections using virus vector controls, AdSurvivin or Ad-T34A treatment (Mesri, Wall et al. 2001, McKay, Bell et al. 2003, Liu,
Brouha et al. 2004). There were also no changes in other IAPs or members of the Bcl-2
family (Liu, Brouha et al. 2004). While Survivin-T34A may not affect endogenous levels
of other IAPs, a Survivin-IAP (XIAP, cIAP1, and cIAP2) complex has been confirmed as
well as suggestion for direct interaction between Survivin and XIAP through their BIR
domains (Dohi, Okada et al. 2004). Furthermore, evidence that T34A can only kill cells
expressing Survivin has been shown in its inability to kill normal human cells treated in
vitro (Mesri, Wall et al. 2001, McNeish, Lopes et al. 2005) and in vivo (Mesri, Wall et al.
2001, Yan, Thomas et al. 2006). However, T34A has shown significant killing affects in
normal endothelial cells that express high levels of endogenous Survivin (Blanc-Brude,
Mesri et al. 2003). Whether this is the result of some interaction between endogenous
Survivin, other IAPs, and the T34A mutant or a competition between them for protein
interactors is currently unknown.
Mechanistic examination of T34A-induced apoptosis revealed mitochondrial
events that preceded caspase activation, including depolarization and the release of cyto-
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chrome c, AIF and Smac/DIABLO (Mesri, Wall et al. 2001, Blanc-Brude, Mesri et al.
2003, Liu, Brouha et al. 2004, Ogura, Watanabe et al. 2008). Also, T34A treatment of
melanoma cells has also been shown to involve Apaf-1, Mcl-1 and PARP cleavage
(Blanc-Brude, Mesri et al. 2003, Liu, Brouha et al. 2004, Zhang, Wang et al. 2008).
Stress-induced cytochrome c release results in apoptosome formation and caspase activation (Boya and Kroemer 2008), thus several groups have reported that caspase-3 may be
important to T34A-induced apoptosis (Mesri, Wall et al. 2001, Blanc-Brude, Mesri et al.
2003, McKay, Bell et al. 2003, Fukuda and Pelus 2004, Liu, Brouha et al. 2004, Wang,
Fukuda et al. 2004, Barrett, Osborne et al. 2009). A significant increase in apoptosis was
reported in ovarian carcinoma cells treated with T34A and caspase-3 in vivo and in vitro
(McKay, Bell et al. 2003). We, however, working in cervical carcinoma HeLa cells, were
unable to show cleavage of caspase-3 or caspase-8, though cleavage of caspase-9 and
caspase-2 was recorded (Khan, Aspe et al. 2009). Further experiments revealed T34Ainduced a reduction in the proforms of caspase-2, caspase-7 and caspase-9, a cleavage of
PARP and an induction of mitochondrial depolarization. Treatment with caspase inhibitors, Z-DEVD-FMK and Z-VAD-FMK, has been shown to counter the effect of T34A
treatment suggesting T34A-induced apoptosis may act through the caspase-dependent
pathway (Liu, Brouha et al. 2004). Additionally, the earliest proapoptotic event observed
in T34A treated cells was nuclear translocation of mitochondrial apoptosis-inducing factor AIF, which triggers both mitochondrial associated apoptosis and caspase-independent
DNA fragmentation (Liu, Brouha et al. 2004). Taken together, Survivin-T34A targets the
intrinsic (Kroemer and Pouyssegur 2008) or mitochondria-associated apoptotic pathway
to induce most probably caspase-dependent and independent apoptosis (Figure 1).
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Survivin is a structurally unique IAP family protein that is activated survivin. T34A-treated cells grew two-fold faster
expressed in mitosis in a cell cycle-dependent fashion and than control cells, whereas T34E cells grew 2.5-fold slower.
localized to components of the mitotic apparatus.5 Survivin Depletion studies showed that only T34A was normally

However, with the exception of one study (Shin, Sung et al. 2001), Survivin has not been
shown to directly inhibit caspases and whether Survivin-T34A disrupts caspase activity
has yet to be fully elucidated. We postulate that Survivin-T34A-induced apoptosis begins
farther upstream in the intrinsic apoptotic pathway initiating mitochondrial depolarization
as well as inhibition of IAPs known to directly inhibit caspases (e.g. XIAP-caspase-3).
The tumor suppressor gene, p53, has been widely studied and is known to induce
apoptosis (Haldar, Negrini et al. 1994, Strobel, Swanson et al. 1996). As a transcription
factor, p53 is activated by a variety of genotoxic and cytotoxic stresses. Upon activation,
p53 prevents the proliferation of genetically compromised cells by regulating the expression of a battery of genes that initiate cell cycle arrest, apoptosis and DNA repair (Figure
2) (Ashcroft and Vousden 1999). Transcriptionally, p53 activates Mdm2, which in turn
targets p53 for ubiquitin proteasome-dependent degradation. In response to stress, a decrease in Mdm2 protein levels and/or its activity and the interaction between Mdm2 and
p53 lead to p53 stabilization (Marine and Lozano). The relationship between Survivin
and p53 may be important, as Survivin regulates cell division and inhibits apoptosis
whereas p53 inhibits cell cycle progression and induces apoptosis (Wang, Fukuda et al.
2004). Survivin was recently shown to be transcriptionally repressed by wild type p53
and when overexpressed in cells sensitive to p53-dependent cell death, markedly inhibited apoptosis induced by ultraviolet light (Hoffman, Biade et al. 2002).
When cancer cells that had been stably transfected with Survivin-T34A were
treated with the DNA damage-inducing Adriamycin, p53 protein levels were significantly
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Figure 2. Survivin-T34A promotes p53-associated apoptosis. Upon activation, p53 prevents the proliferation of genetically compromised cells by regulating the expression of a
battery of genes that initiate cell cycle arrest, apoptosis, and DNA repair. Survivin disruption by T34A treatment of cancer cells resulted in increased p53 protein levels and
proteasomal degradation of Mdm2.
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elevated compared to DNA damage alone or when combined with stably transfected Survivin (Wang, Fukuda et al. 2004). Increased levels of p53 mRNA preceded the elevation
in p53 protein levels seen with T34A-treated cells, suggesting that p53 may be directly
upregulated by Survivin-T34A. Survivin disruption by Survivin-T34A also resulted in the
degradation of Mdm2. Proteasome inhibition and caspase-3 inhibition blocked this Survivin-T34A-associated decrease in Mdm2 resulting in the stabilization of p53. SurvivinT34A was not shown to affect mRNA levels of Mdm2 (Wang, Fukuda et al. 2004). Furthermore, the p53 homologues TAp63, ∆Np63, TAp73 and ∆Np73 were analyzed for
changes following Survivin-T34A treatment. The response of these p53 homologues is
important because TAp63 and TAp73 both transactivate similar genes as p53, whereas
the ∆Np63 and ∆Np73 function as antagonists to p53 and the TA-homologues (Yang,
Kaghad et al. 1998, Irwin and Kaelin 2001, Yang, Kaghad et al. 2002). ∆Np63, TAp73
and ∆Np73 were all decreased in response to Survivin-T34A, while TAp63 was not detectable. These findings suggest that p53 transcription may be differentially regulated by
Survivin-T34A (Wang, Fukuda et al. 2004). Taken together, the ability of Survivin-T34A
to perturb the p53/Mdm2 feedback loop resulting in increasing levels of p53 and p53’s
ability to then transcriptionally repress Survivin may prove to be just the therapeutic
strategy needed for targeting p53-associated stress-induced repair pathways in cancer.

Survivin Threonine 34 Plays a Role in Cell Cycle Regulation
Survivin is a structurally unique IAP family protein that is expressed in mitosis in
a cell cycle-dependent fashion and localized to components of the mitotic apparatus (Li,
Ambrosini et al. 1998). Survivin has been described as bifunctional, in that it is involved
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in both inhibition of apoptosis and control of cell division (Altieri 2003, Altieri 2006). In
order to study the effect Survivin phosphorylation at Thr34 had on cell division, the nonphosphorylatable T34A form of Survivin was compared to T34E, which acts as a
phosphomimetic (Barrett, Osborne et al. 2009). As a phosphomimetic, T34E assumes the
role of a phosphorylated Thr34 and therefore mimics an activated Survivin. T34A-treated
cells grew 2-fold faster than control cells while T34E cells grew 2.5-fold slower. Depletion studies showed that only T34A was normally distributed and able to support cell
proliferation while T34E could not.
Survivin has been known to be upregulated in G2/M of the cell cycle, but T34A’s
ability to induce apoptosis is G2/M-independent (McKay, Bell et al. 2003). The cell cycle
profile of T34A treated cells was normal while T34E treated cells had a significantly increased G2/M population suggesting that cell division failed (Barrett, Osborne et al.
2009). Furthermore, cancer cells which exhibited endogenous levels of functional Survivin, when treated with T34A showed significant mitotic index inhibition (Mesri, Wall
et al. 2001), as well as reduction in colony formation (Khan, Aspe et al. 2009). Ultimately, when endogenous Survivin was depleted, T34A restored Survivin’s mitotic function
while T34E was mitotically incompetent. We therefore conclude that phosphorylated
Thr34 inhibits mitosis (Barrett, Osborne et al. 2009), but non-phosphorylated Survivin is
important for mitosis.
T34A has been shown to decrease the proportion of cells in S-phase following Sphase arrest (Fukuda and Pelus 2004). Evidence for Survivin-T34A regulation of chromosomal passenger complexes and central spindle checkpoint during mitosis has been
generated (Lens, Rodriguez et al. 2006). In this work, Survivin-T34A was also shown to
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be able to restore the spindle checkpoint defect following mitosis arrest unlike the other
non-wildtype forms as well as rescue the cells from cytokinesis failure (Lens, Rodriguez
et al. 2006). These findings strongly suggest Survivin-T34A is a functional complement
for endogenous Survivin. Because Survivin-T34A functionally behaves as Survivin, it
can localize appropriately during mitosis and thus correctly colocalize Aurora B at the
centromeres and midzone (Lens, Rodriguez et al. 2006, Barrett, Osborne et al. 2009), allowing proper mitosis regulation. Further experiments show that Survivin-T34A correctly
localizes BubR1 to the kinetochores and can restore localization of endogenous Borealin/Dasra B to both centromeres and central spindles (Ruchaud, Carmena et al. 2007).
Taken together, Survivin-T34A allows for the enhanced proliferative effects of Survivin
while Survivin-T34E does not. This suggests that the non-phosphorylated Survivin Thr34
(T34A) accounts for cellular proliferation as opposed to the phosphorylated Survivin
Thr34 (T34E). Also, contrasting Survivin Thr34 for its cytoprotective activity revealed that
T34E is responsible for the antiapoptotic characteristics whereas T34A allows for caspase
activation and induced apoptosis (Barrett, Osborne et al. 2009).

T34A Opposes Classical Cancer Characteristics
Angiogenesis is crucial for cell survival and function and without it tumor cells
are not able to obtain oxygen and nutrients. Targeting tumor angiogenesis is a relatively
new therapeutic strategy and it is believed that if the tumor’s oxygen and nutrient supply
is limited, tumor growth and development will be inhibited and may result in apoptosis.
Survivin-T34A treatment of tumor-bearing mice resulted in inhibited tumor-induced angiogenesis and increased apoptosis (Peng, Yang et al. 2008, Li, Zhao et al. 2009, Shan,
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Wang et al. 2010, Yu, Wang et al. 2010). Tumor sections taken from human breast cancer
transplants in mice were stained with anti-CD31 antibody to determine microvessel density (Pan, Peng et al. 2010). Survivin-T34A treated groups showed significantly reduced
microvessel density compared to controls (Peng, Yang et al. 2008). In vivo results
showed T34A-induced apoptotic characteristics in murine endothelial cells as well as decreased new vessel formation when compared to control mice (Blanc-Brude, Mesri et al.
2003, Peng, Yang et al. 2008). Furthermore, experiments using CT26 colorectal cancer
cells showed similar results (Li, Zhao et al. 2009). It is still unknown how Survivin-T34A
treatment reduces tissue staining for the angiogenesis marker CD31. The elucidation of
this mechanism may provide insight into this tumor-acquired capability. Survivin has
been shown to be upregulated by vascular endothelial growth factor (VEGF) (BlancBrude, Mesri et al. 2003), an important promoter of angiogenesis. Perhaps, Survivin
regulation by VEGF promotes angiogenesis by protecting developing vessels from apoptosis. Therefore, Survivin-T34A inhibits VEGF’s promotion of angiogenesis, which may
be mediated through loss of p53, activation of phosphatidylinositol 3’-kinase, or phosphorylation of signal transducers and activators of transcription 3 (Tran, Rak et al. 1999,
O'Connor, Schechner et al. 2000, Papapetropoulos, Fulton et al. 2000, Mahboubi, Li et al.
2001, Harfouche, Hassessian et al. 2002).
Once a tumor mass becomes constricted, cells acquire the ability to invade surrounding tissue and metastasize to distant sites, which accounts for 90% of human cancer
deaths (Hanahan and Weinberg 2000). The inhibition of Survivin using adenoviruses
(Ad-T34A) or short hairpin RNA dramatically inhibited invasiveness of prostate cancer
cells in the in vitro invasion assay, and spontaneous metastasis in the Dunning prostate
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cancer in vivo model (Zhang, Coen et al. 2010). Treatment of subcutaneous breast cancer
tumors in mice using T34A plasmids (Peng, Yang et al. 2008) or Ad-T34A (Mesri, Wall
et al. 2001) inhibited metastasis of breast tumor cells from the primary tumor site to the
lungs and peritoneum, respectively (Peng, Yang et al. 2008). Specifically, control treatment groups were observed to have a greater number of metastatic nodules and structural
destruction of pulmonary alveoli compared to the T34A treatment group in transplanted
mice (Mesri, Wall et al. 2001, Peng, Yang et al. 2008). In light of the role metastasis
plays in cancer death, T34A’s metastasis-inhibitory role is important as current therapeutics offer limited capabilities.
Cancerous lesions promote tumor growth, motility, invasion and angiogenesis via
oncogene-driven immunosuppressive leukocyte infiltrates (Melief 2008). T34A has been
shown to enhance T lymphocyte activity against autologous tumor cells (Peng, Yang et
al. 2008). In addition, T cells derived from mouse xenographs exhibited higher cytotoxicity against target tumor cells in T34A treated mice (Li, Zhao et al. 2009). Further studies
revealed that adoptive transfer of CD8+ T lymphocytes, and not their CD4+ T lymphocyte
counterparts, isolated from the spleen of T34A treated mice exhibited a decrease in tumor
volume. Perhaps the treatment of tumor cells with T34A or with immune cells that have
been primed by Survivin-T34A association will redress the immunosuppression associated with cancer.

Translational Approaches and Obstacles
Given Survivin’s role in chemotherapy and radiation resistance (Mesri, Wall et al.
2001, Wall, O'Connor et al. 2003, Chakravarti, Zhai et al. 2004, Fujie, Yamamoto et al.

16

2005, Zhang, Latham et al. 2005, Zhang, Mukherjee et al. 2005, Ferrario, Rucker et al.
2007, Ogura, Watanabe et al. 2008) results using T34A would suggest its role is to promote sensitivity to chemotherapy and radiotherapy. In the first study to investigate
T34A’s ability to enhance cancer cell chemosensitivity, transfected Survivin-T34Ainduced apoptosis was as effective as Taxol alone, whereas transfected Survivin-T34A
cells enhanced Taxol-induced apoptosis (Mesri, Wall et al. 2001). Subsequent studies involving other chemotherapeutics have also revealed enhanced apoptosis in T34Aexpressing cancer cells and xenograph models (Flutamide (Zhang, Latham et al. 2005),
Paclitaxel (Zhang, Mukherjee et al. 2005)). Survivin-T34A combined with Adriamycin
exhibited no added effect over Adriamycin alone (Mesri, Wall et al. 2001). This study
was followed by studies designed to characterize phosphorylated Survivin Thr34’s protective role. Following Adriamycin treatment of tumor cells, p34(cdc2) was
coimmunoprecipitated with Survivin. These findings suggest that p34(cdc2) phosphorylates Survivin on Thr34 following Adriamycin treatment thus protecting the cells against
the chemotherapeutic. These results were correlated with elevated MPM-2 mitotic phosphoepitope expression (Wall, O'Connor et al. 2003). While Survivin-T34A combined
with Adriamycin exhibited no added effect over Adriamycin alone, it may still be possible to synergistically enhance Adriamycin’s effect with pretreatment of Survivin-T34A.
The same study further showed that increased doses of Flavopiridol treatment were associated with suppression of Survivin Thr34 phosphorylation.
Human glioblastoma multiforme (GBM) cells were treated with adenoviral vectors containing T34A or Survivin, in vivo and in vitro. No change was seen in normal
cells treated with either Survivin form, but radiosensitivity was exhibited in T34A treated
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cells compared to Survivin-treated or control cells. Several other studies have confirmed
similar results suggesting that Survivin only affects radiosensitivity of tumors cells and
radioresistance can be reduced by T34A treatment (Ferrario, Rucker et al. 2007, Ogura,
Watanabe et al. 2008, Barrett, Osborne et al. 2009, Khan, Aspe et al. 2009, Yuan, Wang
et al. 2010). Interestingly, when cancer cells were irradiated and then treated with T34A,
radiosensitivity was enhanced even more (Chakravarti, Zhai et al. 2004). Enhanced radiation sensitivity may be explained by cleavage and activation of caspase-3 in T34A treated
cells. Caspase inhibitors, except those for caspase-9, have been able to reduce apoptotic
phenotypes in X-irradiation of T34A-treated cells (Ogura, Watanabe et al. 2008). Radiosensitivity may also be induced via a caspase-independent mechanism (Chakravarti, Zhai
et al. 2004). DNA double strand breakage was greater in T34A treated cells suggesting
that T34A may interfere with the cell’s ability for DNA repair post irradiation
(Chakravarti, Zhai et al. 2004).

Conclusion
Survivin-T34A has a rich history, having been first utilized as a mimic of nonphosphorylated Survivin, and now as a possible cancer therapeutic. It is full of potential
as a molecular therapy because of its minimal toxicity and its ability to induce apoptosis
and immune modulation while reducing angiogenesis, metastasis and cell cycle progression in Survivin expressing cells (Figure 3). With the discovery that T34A conditioned
medium, taken from cells that overexpress and release Survivin-T34A to the extracellular
space, is able to kill cancer cells in vitro (Khan, Aspe et al. 2009), we hope to further enhance the scientific data banks and pave new paths for clinical modalities and regimens.
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For this to occur however, additional testing of this agent on normal tissues – specifically
testing its myelosuppressive effects, will have to be completed. Also, additional studies to
synergistically enhance chemo-and radiotherapies, whether in combination with or
through Survivin-T34A pretreatment, must be accomplished. The knowledge that will
make this possible includes: the elucidation of Survivin-T34A target cell populations,
cell-surface receptors, changes that occur in the target tissue at the molecular and cellular
level, the presence or development of resistance which could limit its use, the mechanism
of therapeutic action, and its site of action. As Survivin and p53 are important opposing
regulators of cancer, further research on their interactions and signaling pathways will
likely provide specific clues for understanding this complicated relationship.
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Figure 3. Survivin-T34A has therapeutic potential, as it has been shown to induce apoptosis and immune modulation while reducing angiogenesis, metastasis, and cell cycle
progression in Survivin-expressing cells.
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Abstract
The tumor microenvironment is believed to be involved in development, growth,
metastasis, and therapy resistance of many cancers. Here we show Survivin, a member of
the inhibitor of apoptosis protein (IAP) family, implicated in apoptosis inhibition and the
regulation of mitosis in cancer cells, exists in a novel extracellular pool in tumor cells.
Furthermore, we have constructed stable cell lines that provide the extracellular pool with
either wild-type Survivin (Surv-WT) or the previously described dominant-negative mutant Survivin (Surv-T34A), which has proven pro-apoptotic effects in cancer cells but not
in normal proliferating cells. Cancer cells grown in conditioned medium (CM) taken
from Surv-WT cells absorbed Survivin and experienced enhanced protection against genotoxic stresses. These cells also exhibited an increased replicative and metastatic
potential, suggesting that Survivin in the tumor microenvironment may be directly associated with malignant progression, further supporting Survivin's function in
tumorigenesis. Alternatively, cancer cells grown in CM taken from the Surv-T34A cells
began to apoptose through a caspase-2- and caspase-9-dependent pathway that was further enhanced by the addition of other chemo- and radiotherapeutic modalities. Together
our findings suggest a novel microenvironmental function for Survivin in the control of
cancer aggressiveness and spread, and should result in the genesis of additional cancer
treatment modalities.
Keywords: tumor microenvironment, survivin, apoptosis, metastasis
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Introduction
The complexity and heterogeneity of the tumor microenvironment (Tredan,
Galmarini et al. 2007) is believed to have an important function in the development,
growth, metastasis, and therapy resistance of many cancers (Ohtani 1998). The tumor is
not merely a single genotype-containing clonal mass but a community of heterogeneous
cancer cells and stromal cells embedded in an extracellular matrix and nourished by vascular and fibroblast cell networks (Aznavoorian, Stracke et al. 1990).
The multifunctional protein Survivin controls diverse cellular functions, including
surveillance checkpoints, suppression of cell death, the regulation of mitosis, and the adaptation to unfavorable environments (Li, Ambrosini et al. 1998, Altieri 2003, Altieri
2006). The suppression of cell death activities and baculovirus inhibitor of apoptosis protein (IAP) repeat (BIR) domain characterizes Survivin as a member of the IAP family
(Ambrosini, Adida et al. 1997). However, Survivin's lack of a C-terminal RING finger
domain and a caspase recruitment domain (Deveraux and Reed 1999) makes it structurally unique among the mammalian IAPs. The multifaceted functionality of Survivin is still
being intensely scrutinized, although it appears that protein compartmentalization may be
important. Survivin was recently shown to colocalize in the mitochondria, where it abolishes tumor cell apoptosis and promotes tumorigenesis in immunocompromized animals
(Dohi, Beltrami et al. 2004). Survivin may therefore possess a function in apoptosis similar to the pro-apoptotic Bcl-2 family proteins. Furthermore, Survivin has been also found
in the nucleus and cytosol where the implication is that it has functions in mitosis regulation and apoptosis inhibition, respectively (Fortugno, Wall et al. 2002). Survivin is
expressed in most common human cancers and although present during embryonic and
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fetal development, it is undetectable in a variety of adult tissues (Adida, Crotty et al.
1998) and for this reason it is currently recognized as an important anticancer target
(Fukuda and Pelus 2006). For this purpose, multiple strategies have been successfully
investigated, including the molecular antagonists such as antisense oligos, RNA inhibition, dominant-negative mutants, Survivin-specific cytolytic T cells, a nonphosphorylatable Survivin mutant Thr34 → Ala (T34A), and most recently, binding interface mimetics (Olie, Simoes-Wust et al. 2000, Andersen, Pedersen et al. 2001,
Grossman, Kim et al. 2001, Kanwar, Shen et al. 2001, Mesri, Wall et al. 2001, Wall,
O'Connor et al. 2003, Plescia, Salz et al. 2005).
In the present study, we investigate whether extracellular compartmentalization of
Survivin participates in the cytoprotection, tumorigenesis, and enhanced metastasis encountered in the tumor microenvironment. We have identified a novel pool of Survivin,
localized extracellularly that is readily taken up by cancer cells but not by normal stromal
cells. Furthermore, cancer cells that absorb Survivin show enhanced growth patterns and
are more resistant to genotoxic stress than controls containing only endogenous levels of
Survivin. Further investigations to define uptake-induced phenotypes of the apoptosis
inducing non-phosphorylatable Survivin-mutant (T34A) have shown a caspase-dependent
enhancement of chemotherapy-induced cell death, in vitro.

Materials and Methods
Cell Lines and Cultures
Cervical carcinoma (HeLa and HeLa-S), osteosarcoma (U2OS and SaOS2), pancreatic carcinoma (Panc1, Capan1, and Capan2), prostate carcinoma (PC3, DU-145, and
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RWPE-2), and breast carcinoma (MCF-7, HCC 1806) cell lines were obtained from the
American Type Culture Collection (ATCC) as were the human normal prostate stromal
cells (PrSC). The acute monocytic leukaemia cell lines (MOLM-14 and MV4-11) were a
kind gift from CS Chen (Loma Linda University). Normal prostate epithelial cells (PrEC)
were obtained from Clonetics-BioWhittaker (Walkersville, MD, USA) and cultured in
PrEMB medium (Clonetics-BioWhittaker). The normal human bone marrow stromal
(HBMS) cells were a generous gift of Kimberly Payne (Loma Linda University). Stromal
cells were isolated and propagated as previously described (Hao, Shah et al. 1995) from
adult human bone marrow that was purchased from Poietics Cell Systems (Lonza Walkersville Inc., Gaithersburg, MD, USA). Human peripheral blood mononuclear cells were
isolated from a peripheral blood draw using Ficoll-Hypaque (GE Healthcare BioSciences Corp., Piscataway, NJ, USA) as has been previously described (Wang, Azzo et
al. 1984). The use of all human tissues was reviewed and approved by the institutional
review board at Loma Linda University with informed written consent obtained from
each subject. Cells were maintained as defined in DMEM, McCoy's, RPMI, or IMEM
(ATCC) supplemented with 100 U of penicillin, 100 μg ml−1 streptomycin, 300 μg of lglutamine, and 10–20% heat inactivated fetal bovine serum (FBS; ATCC). Cells were
grown at 37°C in a humidified atmosphere of 95% air, 5% CO2 until 60% confluent and
supernatants were removed. New medium was given and cells were grown to 90% confluent, after which supernatants were collected, centrifuged for 10 min at 2500 r.p.m.,
and stored at −20°C until use.
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Expression Plasmid and Generation of Stable Cell Lines
The detailed procedure for cloning and propagation has been described previously
(Ogawa, Ishiguro et al. 2002, Shi, Sawada et al. 2003). In brief, recombinant retroviruses
expressing a bicistronic messenger RNA containing open-reading frames of Flag-HA
(hemagglutinin)-tagged human Survivin or human T34A-Survivin and interleukin-2 receptor (IL-2R)-α were constructed and transduced into HeLa cells. The infected HeLa
cells were sorted by anti-IL-2R monoclonal antibody (mAb) conjugated with magnetic
beads, and the resulting Flag-HA-Survivin or Flag-HA-T34A-Survivin stable cell lines
propagated as suspension cultures. The expression level of both the wild-type (WT) and
mutant (T34A) Survivin was evaluated by western analysis and immunohistochemistry
with anti-Flag and HA antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA).

Survivin Depletion
Conditioned medium (CM) from stable Survivin-expressing HeLa cells contains
Survivin that has a Flag-HA tag as well as normal endogenous Survivin. To deplete the
medium of Survivin, we added anti-Flag beads (20 μl/ml) to the medium and rotated
overnight at 4°C. The medium was centrifuged at 2000 r.p.m. for 5 min to pellet the
beads. The supernatant was collected and 100 μl set aside for analysis by ELISA. The
pelleted beads were collected and put in at −20°C. The remaining medium was treated
with anti-HA beads (20 μl/ml) in a similar manner to remove the remaining tagged Survivin. To deplete the endogenous Survivin, we added anti-Survivin polyclonal antibodies
(10 μl/ml) and anti-rabbit beads (20 μl/ml) to the medium and rotated overnight at 4°C.
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The 100 μl aliquots at each stage were used in an ELISA to confirm the depletion. The
beads collected at each step were incubated in 40 μl sample loading buffer at 100°C for 4
min, then centrifuged at 2000 r.p.m. for 5 min. A western blot of the supernatant was
used to further confirm depletion.

Quantitation of Survivin from CM
(Cell Culture Supernatants)
Conditioned medium was collected from 90% confluent cell cultures with cell viability assessed by Trypan blue exclusion (Sigma-Aldrich, St Louis, MO, USA). Onehalf of the medium was concentrated 4 × using a speed-vac (Savant OligoPrep 120) after
which unconcentrated and concentrated samples were assayed for the presence of Survivin using the Quantikine Human Survivin immunoassay kit (R&D Systems Inc.,
Minneapolis, MN, USA), according to the manufacturer's instructions. To quantify representative Survivin protein from cultures experiencing cell death, we grew HeLa cells to
90% confluence as previously described after which 0.1, 1.0, and 10% of these cells were
lysed and their protein used to ‘spike' control medium for ELISA.

Immunofluorescence Localization of Protein
Cells were plated in six-well plates on 22 × 22 mm coverslips and cultured with 2
ml of control or CM (Surv-WT-CM, Surv-T34A-CM). Wells were washed with PBS and
fixed in 4% paraformaldehyde for 30 min at room temperature. Cells were permeabilized
with 0.5% NP-40 in PBS for 15 min, blocked with 5% FBS in 0.01% NP-40/PBS for 30
min, incubated for 1 h with 1 : 500 dilution of anti-Flag/HA mAbs (Sigma-Aldrich).
Cells were incubated with Alexa Fluor-555-conjugated rabbit anti-mouse IgG secondary
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antibody (Invitrogen/Molecular Probes, Eugene, OR, USA), mounted with Vectashield
mounting media containing DAPI (Vector Laboratories, Burlingame, CA, USA) and observed (× 1000) under an Olympus BX50 fluorescent microscope (Olympus America
Inc., Center Valley, PA, USA).

Image Acquisition Using Laser-scanning Confocal Microscopy
Sampled sections were imaged and analyzed with an Olympus FV 1000 laserscanning confocal imaging system mounted onto an Olympus IX81 microscope (Olympus America Inc.). Microscopic data were acquired with a 60× oil immersion objective
lens. In each section, confocal stack images from representative fields of view per section
were captured. The distance between each focal plane was 1 μm.

Protein Expression and Purification
Recombinant WT or mutated (T34A) proteins were expressed as glutathione-Stransferase (GST) fusion proteins in the Escherichia coli BL21-CodonPlus-RIL (Stratagene, La Jolla, CA, USA) strain with induction in 0.2 mm isopropyl-β-dthiogalactopyranoside (IPTG) for 5 hrs. at 30°C. BIRC5 (Survivin) was purchased from
Abnova (Walnut, CA, USA). The cells were harvested by centrifugation at 6000 g for 20
min, suspended in 50 mm Tris (pH 7.4), 150 mm NaCl, 5 mm MgCl2, and 1 mm dithiothreitol, and lysed by sonication. After centrifugation at 15 000 g for 30 min, we mixed
the soluble fractions with glutathione-agarose beads (Sigma-Aldrich) and incubated for 1
h at 4°C. After centrifugation at 1000 g for 1 min, we washed beads containing proteins
three times in 50 mm Tris (pH 7.4), 500 mm NaCl, 5 mm MgCl2, and 1 mm dithio-
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threitol and further purified by chromatography over Econo-Column (Bio-Rad, Hercules,
CA, USA) after overnight thrombin (Sigma-Aldrich) treatment to release the GST frame.
The protein concentrations were measured using a protein assay reagent (Pierce, Rockford, IL, USA) with BSA as standard. Recombinant transferrin protein was purchased
from Sigma-Aldrich. The expression vector PRSET-CTB contained a gene encoding the
entire cholera toxin B subunit (CTB) protein (11.6 kDa), driven by the T7 bacteriophage
promoter region and containing an oligonucleotide encoding 6 histidines immediately
upstream of the CTB gene for nickel column isolation of the recombinant protein was
built as described (Carter, Yu et al. 2006). Briefly, CTB protein synthesis was stimulated
by addition of 90 mg IPTG to the bacterial culture for 6 h at 37°C. Cells were harvested
by centrifugation with the pellet resuspended in 10 mm HEPES buffer (pH 7.5), containing 100 mm imidazole. The cells were disrupted by sonication at 3 × 10 s bursts at 10 W,
with a Sonic 60 Dismembrator. Cholera toxin B subunit protein was isolated from the
homogenate by a Maxwell Model 16 robotic protein purification system (Promega Inc.,
Madison, WI, USA), according to the protein isolation protocol provided by the manufacturer. Purity of the isolated CTB protein was determined by electrophoretic mobility
measurement in a 12% polyacrylamide gel. Imidazole was removed from the protein
mixture by dialysis of the preparation against 10 mm HEPES buffer (pH 7.5), for 4 hrs. at
4°C.

IR-Dye Labeling of Recombinant Proteins and In-cell
Western Blotting
IR-Dye labeling was performed according to the manufacturer's instructions (LICOR Biosciences, Lincoln, NE, USA). Briefly, 100 μg of transferrin, CTB, and 10 μg of
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BIRC5 was labeled at 20°C for 2 hrs.. Labeled protein was column purified as described
by the manufacturer. HeLa cells (5 × 103 per well) were plated in 96-well plates. After
overnight culture, we added labeled BIRC5, transferrin, and CTB proteins at doses of 1
μg, 0.01 μg, and 0.001 μg in duplicate wells. After overnight culture, we washed cells
vigorously 3–4 times with PBS to remove all remaining unattached recombinant protein.
Cells were fixed with 4% paraformaldehyde and an in-cell western blot was performed
using Survivin polyclonal antibody (Novus, Littleton, CO, USA) according to the manufacturer's instructions. The 96-well plate was then scanned immediately in both 700 and
800 nm channels. Relative fluorescent intensity was determined using our Odyssey Infrared Imaging system and software.

Colony Formation Assay
The cells were plated in 10 cm dishes at a density of 100 000 cells per well, incubated at 37°C overnight, and then were treated with the indicated control, Surv-WT-CM,
and Surv-T34A-CM for up to 48 hrs.. The cells were fixed with methanol and stained
with crystal violet.

Cell Cycle Synchronization
HeLa-S cells were G1-arrested for 16 hrs. using mimosine as previously described (Li, Ackermann et al. 1999). Cells were then released and treated with either
Surv-WT-CM or control medium and then harvested after 0, 3, 6, 9, and 12 hrs.. Cells
were analyzed for DNA content by propidium iodide staining and flow cytometry (Becton Dickinson, San Jose, CA, USA).
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Apoptosis and Cell Cycle Analysis
Subconfluent cultures of the various cell lines were incubated with vehicle
(DMSO), taxol (4 μm; Sigma-Aldrich), 5-flurouracil (5-FU, 200 nm; Sigma-Aldrich),
adriamycin (Ad, 100 nm, Sigma-Aldrich), cisplatin (CDPD, 2 μm; Sigma-Aldrich) or exposed to ultraviolet B (UVB) irradiation at 50 J m−2 with or without the presence of WTCM, T34A-CM, or control for 24 and 48 hrs. at 37°C. Cells were harvested, prepared,
and analyzed for DNA content as described previously (Li, Ackermann et al. 1999). DNA
content was analyzed using a Becton Dickinson FACScan flow cytometer (Becton Dickinson). The distribution of cells in the different phases of the cell cycle was analyzed
from DNA histograms using BD CellQuest software (Becton Dickinson).

AlamarBlue (AB) Assay for Cell Proliferation
Initial experiments were carried out to follow per cent AB (%AB) reduction over
time. The aim was to determine the optimal seeding density and culture period. HeLa
cells, trypsinized from subconfluent cultures as described earlier, were suspended in culture medium containing 1% FBS, T34A-CM, and WT-CM and then seeded into duplicate
wells of a 96-well plate (200 ml well) at concentrations of 1.5 × 104–1 × 106 cells per ml
at standard culture conditions of 5% CO2 in air at 37°C. After an initial 4 hrs. period to
allow for cell attachment, we added AB (BioSource, Camarillo, CA, USA) directly into
culture medium at a final concentration of 10% and the plate was returned to the incubator. Optical density of the plate was measured at 540 and 630 nm with a standard
spectrophotometer at 1, 3, 6, 12, 24, 48, and 72 hrs. after adding AB. Because the culture
medium was not changed during this period, the calculated %AB reduction is a cumula-
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tive value. As a negative control, AB was added to medium without cells.

Caspase Activity Assay
Caspase activity was quantitated using the ApoAlert Caspase Assay Plates (Clontech, Mountain View, CA, USA). Fluorogenic substrates specific for caspase-3, caspase8, caspase-9, and caspase-2 were immobilized in the wells of a 96-well plate. Fluorescence was detected using a standard fluorescence plate reader in the presence or absence
of the specific caspase inhibitor.

Western Blot Analysis
Cells were solubilized, proteins (20–40 μg) separated using 12% Bis-Tris polyacrylamide gels, proteins transferred onto polyvinylidene difluoride membranes
(Millipore, Temecula, CA, USA) and probed using the following antibodies: mouse
monoclonal anti-Flag and anti-HA (Sigma-Aldrich), rabbit polyclonal anti-Survivin
(Novus), rabbit polyclonal antibodies to caspase-7, caspase-9, PARP and GAPDH (Cell
Signaling Technologies, Beverly, MA, USA), mouse mAbs to β-actin (Abcam, Cambridge, MA, USA), and mouse mAb to caspase-2 (Cell Signaling Technologies).
Secondary antibodies (IR-Dye-conjugated) were goat anti-rabbit and goat anti-mouse
immunoglobulin (LI-COR Biosciences). Immunoreactive bands were detected using the
Odyssey imaging system (LI-COR Biosciences) and quantified using ImageQuant software (Amersham Biosciences, Piscataway, NJ, USA). Protein quantifications presented
in this report were normalized with respect to β-actin or GAPDH.
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Mitochondrial Permeability Detection
Mitochondrial depolarization is detected by a unique fluorescent cationic dye
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzamidazolocarbocyanin iodide, also known as
JC-1 (Invitrogen/Molecular Probes). Cells were collected and washed with PBS and prepared for the analysis according to the manufacturer's instructions.

Collagen Cell Invasion Assay
Cellular invasion was studied using the QCM 96-well Fluorometric Collagenbased Cell Invasion Assay from Chemicon International (Millipore) according to the
manufacturer's instructions. Briefly, single-cell suspensions were obtained by trypsinization of monolayer cultures of HeLa cells. Cell counts and viability were performed using
Trypan blue staining after overnight serum starvation. Cells (25 000 cells per well) were
plated on 8 μm pore size collagen-coated inserts in 96-well plates. Cells were grown for
24 h with control media, Surv-WT-CM, Surv-T34A-CM, medium that was depleted of
Survivin introduced into the lower chamber or medium taken from cells treated with cytochalasin D, a known inhibitor of exocytosis that works by specifically disrupting
microfilaments. Survivin was depleted using one round of anti-Flag antibody, one round
of anti-HA antibody, and either 1 (depleted 1 × ) or 3 (depleted 3 × ) rounds of antiSurvivin antibody. A control, termed blank, was performed using only cell detachment
buffer, lysis buffer, and CyQuant dye without cells. Invasive cells, migrating through the
polymerized collagen layer, were dissociated using cell detachment buffer as described
by the manufacturer and lysed. Fluorescence emission (CyQuant GR dye) was assessed
by a fluorescent plate reader (Molecular Dynamics, Sunnyvale, CA, USA).
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Statistical Analysis
Statistical analysis was performed using a two-way analysis of variance with the
aid of JMP statistical software (Cary, NC, USA). A paired t-test was used for group analysis. Caspase-2, caspase-7, and caspase-9 densitometric analysis was conducted using our
AlphaImager EC (Alpha Innotech, San Leandro, CA, USA). Density of individual bands
was divided by GAPDH as the internal control with each timed sample then divided by
the particular time period control. As 6 hrs. staurosporine did not have a 6 hrs. control,
these were also controlled against the 24 hrs. control samples.

Results
Stable Expression of Wild-Type and Mutant T34A Survivin
leads to Survivin Secretion
We and others (Bokarewa, Lindblad et al. 2005, Mera, Magnusson et al. 2008) recently found and reported a form of Survivin that is found in the extracellular space.
Using a commercially available Survivin ELISA, we were able to quantitate picogram
amounts of Survivin from CM taken from tumor cell lines representative of the most
common cancer types, including pancreatic, breast, prostate, cervical, sarcoma, and acute
monocytic leukaemia (Table 1). To determine whether this extracellular form of Survivin
was merely released as a result of an excretory process, the result of cellular necrosis, or
whether its function was secretory and would be important in the context of the tumor
microenvironment, that is absorbed into cells, we needed to construct a form of Survivin
different from the endogenous form. We therefore generated stable HeLa cells expressing
human Survivin (Surv-WT) tagged with both the Flag and HA epitopes at their N terminus. Immunohistochemistry (Figure 4A) as well as western blotting (Figure 5) using
34

antibodies to either HA or Flag revealed the Survivin fusion protein. The Surv-T34A mutant has shown promise in initiating the mitochondrial apoptotic pathway (Mesri, Wall et
al. 2001) and if also detected extracellularly could provide a form of Survivin suitable for
therapeutic manipulation. We therefore generated stable HeLa cells expressing the nonphosphorylatable Surv-T34A mutant. Immunohistochemistry (Figure 4B) and western
blotting (Figure 5) revealed the HA-Flag-Survivin fusion protein. The generation of this
cell line took many attempts, and many months, as the Surv-T34A mutant was very toxic
to the HeLa cells. Further analysis of allowing mutations has not yet taken place.
Conditioned medium taken from these stable Surv-WT or Surv-T34A HeLa cells
showed picogram amounts of Survivin by ELISA (Table 1). Interestingly, it was quite
apparent that accumulation of the T34A mutant Survivin and that from the parent HeLa-S
cells was limited in comparison to that which accumulated in the medium from the SurvWT cells (Table 1). To evaluate this disparity, we evaluated Survivin protein concentration, determined using ELISA, on a per cell basis. Dividing the measured amount of
protein by the number of cells that were present provides evidence that the Surv-WT cells
truly do release more protein into the CM than does the control cells or the Surv-T34Aproducing cells (Figure 6A). AB staining was next used to determine if this phenomenon
was the result of cellular division. As recorded in Figure 6B, AB reduction in the SurvWT HeLa-S cells represented a state of enhanced cellular growth when compared to the
controls or the Surv-T34A cells. Surv-T34A HeLa-S cell proliferation is significantly reduced when compared to the Surv-WT and control HeLa-S cells. Also, there was no
significant difference in the level of cell proliferation recorded in the Surv-T34Aexpressing cells when compared to medium where no cells were being grown (Figure 6B,
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blank), indicating that Surv-T34A may reduce the level of released Survivin as a result of
its stifling cell growth. We next evaluated the functional importance of this extracellular
Survivin protein. HeLa cells were incubated for 24 h in CM taken from control, SurvWT, or Surv-T34A stable cells. Immunohistochemical staining (Figure 7A) and western
blotting (Figure 7B), using antibodies to HA, showed that the Survivin fusion proteins are
readily taken up. A retarded band of approximately 18 kDa appeared in the HeLa-S lysates of cells incubated in WT- and T34A-CM representing the Flag-HA-Survivin fusion
protein (Figure 7B), which was not observed in control conditioned medium grown HeLa
cells. Interestingly, the cells that were incubated in Surv-T34A-CM took on a shrunken
appearance and were fewer in number compared to the control medium-incubated cells
(Figure 7A) whereas the Surv-WT, CM-incubated cells appeared to be healthier and in
greater numbers. Phase-contrast microscopy allowed enhanced visualization of this
shrunken phenotype and the initiation of apoptotic bodies in these T34A-CM-treated
cells. To ensure that the ability of cells to uptake Survivin from the CM was a general
occurrence and not specific for the HeLa cells, we also incubated Capan1, Capan2, MCF7, Panc1, PC3, SaOS2, U2OS, HCC, and HBMS cells in HA-Flag-survivin-containing
CM. All cancer cells were able to take up the Survivin from the medium whereas the
normal HBMS cells did not (Figure 8A). Western blots (Figure 8B) from these cells confirmed the uptake results as every cell type except HBMS, when incubated in Surv-WTCM, expressed 18 kDa band representing the Flag-HA-Survivin fusion
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Figure 4. HeLa cells express the Flag-HA-Survivin fusion protein. Wild type Survivin
(A) and T34A mutant Survivin (B) transformed HeLa cells were selected
four
times usSupl.
Figure
1B
ing magnetic beads conjugated to the IL-2 Receptor antibody. Cells were fixed and
stained using HA and Flag antibodies as described in the methods and materials. Magnification x1000.
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Statistical analysis
Statistical analysis was performed using a two-way analysis of
variance with the aid of JMP statistical software (Cary, NC, USA).
A paired t-test was used for group analysis. Caspase-2, caspase-7,
and caspase-9 densitometric analysis was conducted using our
AlphaImager EC (Alpha Innotech, San Leandro, CA, USA). Density
of individual bands was divided by GAPDH as the internal control
with each timed sample then divided by the particular time period
control. As 6h staurosporine did not have a 6h control, these were
also controlled against the 24h control samples.

mitochondrial apoptotic pathway (Mesri et al, 2001) and if also
detected extracellularly could provide a form of survivin suitable
for therapeutic manipulation. We therefore generated stable HeLa
cells expressing the non-phosphorylatable Surv-T34A mutant.
Immunohistochemistry (Supplementary Figure 1B) and western
blotting (Supplementary Figure 1C) revealed the HA-Flag-survivin
fusion protein. The generation of this cell line took many attempts,
and many months, as the Surv-T34A mutant was very toxic to the
HeLa cells. Further analysis of allowing mutations has not yet
taken place.
Conditioned medium taken from these stable Surv-WT or
Surv-T34A HeLa cells showed picogram amounts of survivin by
ELISA (Table 1). Interestingly, it was quite apparent that

Table 1. Quantitative analysis of Survivin in conditioned medium of cancer cell lines by ELISA
T able 1

Quantitative analysis of survivin in conditioned medium of cancer cell lines by ELISA

Cell t ype

Cell lines

Cervical cancer

HeLa
HeLa-S
HeLa-S-Surv-WT
HeLa-S-Surv-T34A
HeLa-S-survivin
Antibody depletion
Capan1
Capan2
Panc1
PC3
Du-145
RWPE-2
U2OS
SaOS2
MCF-7
HCC TN
MOLM-14
MV4-11
HBMS (normal)
PrECs (normal)
PrSCs (normal)
PBMCs (normal)
Media control
0.1% lysed cells
1.0% lysed cells
10% lysed cells

Pancreatic cancer

Prostate cancer
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Osteosarcoma
Breast cancer
Acute monocytic leukaemia
Human bone marrow stroma
Prostate epithelial cells
Prostate stromal cells
Peripheral blood mononuclear cells
Media control
Spiked media control

pg m l

1

s.e.m .

Concent r at ed (pg m l

1

)

s.e.m .

ND
94.0
619.0
35.2
ND

—
42.1
24.3
0.01
—

330.4
746.1
1158.3
81.9
ND

11.4
1.4
32.1
0.01
—

246.9
ND
20.4
73.3
136.9
29.0
ND
405.4
63.0
ND
ND
ND
ND
ND
ND
ND
ND
ND
77.6
259.7

13.6
—
42.9
32.9
37.4
16.0
—
50.0
2.0
—
—
—
—
—
—
—
—
—
1.1
8.3

1204.7
26.1
174.7
888.3
771.9
337.6
210.4
858.3
175.4
19.0
273.3
347.6
ND
ND
ND
ND
ND
3.2
121.9
596.1

14.3
8.6
47.1
5.0
24.0
7.0
14.3
50.7
1.7
1.4
23.3
15.9
—
—
—
—
—
0.7
2.0
37.0

ND ¼ none detected.
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mean±s.e. of three independent experiments (*P<0.001) as compared to the control.
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protein. Previous work performed on neutrophils showed Survivin not entering the cells
but binding to the surface (Mera, Magnusson et al. 2008). It was therefore necessary to
perform confocal microscopy to ensure Survivin's relocalization within the cells. Taking
photographs at 1 μm increments throughout the cell (shown schematically in Figure 10K)
indicated that in these HeLa cells, Survivin was not only inside the cells but also relocalized within the cytoplasm and to the nucleus (Figure 10).

Relationship Between Survivin Absorption, Surv-T34A-induced
Apoptosis, and Surv-WT-induced Cell Cycle Progression
Consistent with the data presented in Figure 7A, HeLa cells grown in CM taken
from stable Surv-T34A cells experienced enhanced numbers of hypodiploid cells, that is,
sub-G1 DNA content or apoptotic cells (Figure 11A, inset) by DNA content analysis and
flow cytometry. Furthermore, Trypan blue exclusion and colony formation assay evaluation of these same cells showed a time-dependent, marked reduction in live cell numbers
and live cell colonies in the Surv-T34A-CM-grown HeLa cells compared with cells
grown in control medium or the CM from the Surv-WT cells (Figures 11A and B and
Figure 9). This cell number reduced even further after 48 h as shown by the live cell colonies in the Surv-T34A-CM-grown HeLa cells, a finding that is consistent with what has
been recorded by our own group and others (Mesri, Wall et al. 2001, O'Connor, Wall et
al. 2002, Wall, O'Connor et al. 2003, Ogura, Watanabe et al. 2008) that the dominantnegative Survivin mutant T34A induces as caspase-dependent apoptosis. In contrast,
Trypan blue exclusion and colony formation assay evaluation of Surv-WT-CM-grown
cells showed a time-dependent, marked increase in live cell numbers (four times) and live
cell colonies (approximately two times), in comparison with cells
41
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numbers of hypodiploid cells, that is, sub-G1 DNA content or
apoptotic cells (Figure 5A, inset) by DNA content analysis and
flow cytometry. Furthermore, Trypan blue exclusion and colony
formation assay evaluation of these same cells showed a timedependent, marked reduction in live cell numbers and live cell
colonies in the Surv-T34A-CM-grown HeLa cells compared with
cells grown in control medium or the CM from the Surv-WT cells
(Figures 5A and B and Supplementary Figure 2). This cell number

Surv-T34A cells (Figures 5A and B and Supplementary Figure 2).
To further evaluate the cell-cycle progression effects observed in
the Surv-WT-CM-grown cells, we mimosine synchronised HeLa
42cells for 16h, which effectively arrested cells in the G0/G1 phase of
the cell cycle. Mimosine was then removed and the cells were
incubated in the absence or presence of Surv-WT-CM. Cells were
then harvested at 0, 3, 6, 9, and 12h time points following CM
addition and cells were analysed by DNA content analysis and flow
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Figur e 3 Cancer cells but not normal cells incubated in Surv-WT-conditioned medium take up the Flag-HA-survivin fusion protein. (A ) HeLa, Capan1,
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Figure 8. Cancer cells but not normal cells incubated in Surv-WT-conditioned medium
take up the Flag-HA-Survivin fusion protein. (A) HeLa, Capan1, Capan2, MCF-7, Panc1,
PC3, SaOS2, U2OS, HCC, and HBMS cells were cultured with control- or Surv-WTconditioned
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survivin recombinant protein (BIRC5) at the same concentrations
was not endocytosed (Figure 6). Transferrin (Sandvig and van
Deurs, 1990) and CTB (Gizurarson et al, 1992; Frey et al, 1996;
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Figure 9. Surv-T34A conditioned medium induces tumor cell apoptosis while Surv-WT
conditioned medium promotes cell growth. Cervical Carcinoma HeLa cells grown in the
presence of either Surv-T34A or Surv-WT conditioned medium forSupl.
24 andFigure
48 hours, 2
were fixed with methanol and stained with crystal violet allowing visualization of the enhanced cellular proliferative effects of Surv-WT or the killing/growth repressive effects
of Surv-T34A. Plates shown are representative of one of two independent experiments
with comparable results.
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grown in control medium or the CM from the Surv-T34A cells (Figures 11A and B and
Figure 9).
To further evaluate the cell-cycle progression effects observed in the Surv-WTCM-grown cells, we mimosine synchronized HeLa cells for 16 hrs., which effectively
arrested cells in the G0/G1 phase of the cell cycle. Mimosine was then removed and the
cells were incubated in the absence or presence of Surv-WT-CM. Cells were then harvested at 0, 3, 6, 9, and 12 hrs. time points following CM addition and cells were
analyzed by DNA content analysis and flow cytometry. In comparison with cells grown
in control medium, Surv-WT-CM-grown cells had a 10 – 12% increase in S-phase
growth in cells harvested after 6 hrs. and a 10% increase in the number of cells in G2/M
by 12 hrs. (Figure 11C). These findings are consistent with those published indicating
that Survivin displays both anti- apoptosis and promotion of mitosis in cancer cells (Li,
Ambrosini et al. 1998, O'Connor, Grossman et al. 2000, Chao, Su et al. 2007). We are
further encouraged as our CM containing fusion proteins may prove useful for the future
study of Survivin trafficking and T34A therapy in vivo.

Recombinant Survivin Protein Lacks the Function
of Survivin-containing CM
Recombinant Surv-WT and Surv-T34A proteins were incapable of affecting cell
growth or apoptosis in our hands (Figure 12). It is uncertain whether bacterial-derived
Survivin proteins are folded or modified properly for recognition by cellular mechanisms
of uptake. To test this hypothesis further, we evaluated recombinant Survivin, transferrin,
and CTB proteins for cellular uptake using in-cell western assay
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Figure 10. Confocal microscopy indicates that Survivin protein is taken up by cancer
cells and is not merely binding to the cell surface. Cells were fixed and stained with antibodies to HA, with pictures taken on a z-scalenon-cleaved
of 1 μm,forms
magnification
× 1000. (A–J) are
Hansen et al, 2005) recombinant proteins were previously
of caspase-2, caspase-7, and caspase-9 and the
z-scale
taken
at 1μm
as represented
in (K).
described
as pictures
substrates for
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and were used
as
cleaved form
of caspase-3 protein and staurosporine again as a
positive controls.

Character isation of tumour cell apoptosis induced by
Surv-T34A in vitro

positive control, we found that Surv-T34A induced the parallel
time-dependent reduction in caspase-2, caspase-7, caspase-9, and
cleavage of the DNA repair protein PARP (Figure 7B). In all cases
the pan-caspase inhibitor Z-VAD-FMK was able to inhibit the
activity of Surv-T34A. In contrast, Surv-WT again had no observable effects on caspase cleavage when cells were treated with it
alone for up to 48h. Caspase-3 was robustly cleaved after 6h
of staurosporine treatment. However, this cleavage product was
absent after 24h indicating a complete cleavage and degradation of
caspase-3. Concomitant with this cleavage was the significant level
of PARP cleavage recorded at this 24h time point.

We have shown in Figures 2A and 5A that incubating HeLa cells
with Surv-T34A-CM resulted in apoptosis. Cytofluorometric
quantification results showed that in comparison with control
media or Surv-WT-CM treatment, Surv-T34A treatments induced
robust results within 24 to 48h. Previous studies performed, using
an adenovirus-encoding T34A mutant, resulted in apoptosis that
was associated with the mitochondrial release of cytochrome c,
cleavage of caspase-9, and the processing of caspase-3 (Mesri et al,
Loss of mitochondrial membrane potential after treatment
2001). Further analysis of Surv-T34A-CM-induced apoptosis, using
with Surv-T34A CM
a commercially available caspase activity assay, revealed that
Surv-T34A induced cleavage of caspase-9 and caspase-2 without
Mitochondrial membrane potential (Dc m), a phenomenon readily
cleaving the substrates specific for caspase-3 or caspase-8
measured using the mitochondrial dye JC-1 and fluorescence(Figure 7A). The antibiotic and protein kinase inhibitor, stauroactivated cell sorting analysis (Salvioli et al, 1997), was evaluated
sporine, was used as a positive control for caspase-3 activity. Surv- 46 for the possibility that Surv-T34A was stimulating apoptosis by
WT-CM had no effect on the caspase activity under evaluation.
inducing depolarisation within the mitochondria. Under normal
In addition, western blotting provided biochemical data that
circumstances, JC-1 accumulates in the inner mitochondrial
supported studies recorded above for caspase-2, caspase-3, and
membrane in which it oligomerises and fluoresces red. A reduction
caspase-9. Using antibodies that were specific for the full-length,
in Dc m results in diffusion of the dye from the mitochondria and a
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always slower than that seen for staurosporine (Figure 7C). This
may indicate that mitochondrial depolarisation due to Surv-T34A
is a secondary event and not the primary effect of Surv-T34Ainduced killing or that mitochondrial depolarisation is one of
many factors involved in Surv-T34A-induced killing.

Effect of Surv-T34A and Surv-WT and UV radiation on
tumour cell apoptosis

Effect of Surv-T34A and Surv-WT and chemotherapeutic

47drugs on tumour cell apoptosis
To establish that the effects recorded in HeLa cells were not
specific for this cell line alone or for UV radiation, we selected
human pancreatic adenocarcinoma (Capan1 and Capan2) cell lines
to study drug sensitivity and responsiveness in the presence or

Cell Number x 10-5

Supl. Figu

Figure 12. Recombinant Survivin does not affect cell growth (Surv-WT) or life (SurvT34A). HeLa cells were grown in increasing quantities of recombinant Surv-WT or
Surv-T34A protein (1pg, 10pg, 100pg and 1ng) for 24 and 48 hours. Cells were harvested, stained with Trypan blue and counted.
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methods (Egorina, Sovershaev et al. 2005). HeLa cells were incubated with increasing
concentrations of labeled recombinant protein, and the amount of protein endocytosed
after a 12 hrs. incubation was measured as shown in Figure 13. The amount of transferrin
and CTB proteins endocytosed increased in a dose-dependent manner. However, Survivin
recombinant protein (BIRC5) at the same concentrations was not endocytosed (Figure
13). Transferrin (Sandvig and van Deurs 1990) and CTB (Gizurarson, Tamura et al.
1992, Frey, Giannasca et al. 1996, Hansen, Dalskov et al. 2005) recombinant proteins
were previously described as substrates for endocytic uptake and were used as positive
controls.

Characterization of Tumor Cell Apoptosis Induced by Surv-T34A
in vitro
We have shown in Figures 7A and 11A that incubating HeLa cells with Surv-T34ACM resulted in apoptosis. Cytofluorometric quantification results showed that in comparison with control media or Surv-WT-CM treatment, Surv-T34A treatments induced
robust results within 24 to 48 hrs.. Previous studies performed, using an adenovirusencoding T34A mutant, resulted in apoptosis that was associated with the mitochondrial
release of cytochrome c, cleavage of caspase-9, and the processing of caspase-3 (Mesri,
Wall et al. 2001). Further analysis of Surv-T34A-CM-induced apoptosis, using a commercially available caspase activity assay, revealed that Surv-T34A induced cleavage of
caspase-9 and caspase-2 without cleaving the substrates specific for caspase-3 or caspase8 (Figure 14). The antibiotic and protein kinase inhibitor, staurosporine, was used as a
positive control for caspase-3 activity. Surv-WT-CM had no effect on the caspase activity
under evaluation. In addition, western blotting provided biochemical data that supported
49

studies recorded above for caspase-2, caspase-3, and caspase-9. Using antibodies that
were specific for the full-length, non-cleaved forms of caspase-2, caspase-7, and caspase9 and the cleaved form of caspase-3 protein and staurosporine again as a positive control,
we found that Surv-T34A induced the parallel time-dependent reduction in caspase-2,
caspase-7, caspase-9, and cleavage of the DNA repair protein PARP (Figure 15). In all
cases the pan-caspase inhibitor Z-VAD-FMK was able to inhibit the activity of SurvT34A. In contrast, Surv-WT again had no observable effects on caspase cleavage when
cells were treated with it alone for up to 48 hrs.. Caspase-3 was robustly cleaved after 6
hrs. of staurosporine treatment. However, this cleavage product was absent after 24 hrs.
indicating a complete cleavage and degradation of caspase-3. Concomitant with this
cleavage was the significant level of PARP cleavage recorded at this 24 hrs. time point.

Loss of Mitochondrial Membrane Potential After Treatment
with Surv-T34A CM
Mitochondrial membrane potential (Δψm), a phenomenon readily measured using
the mitochondrial dye JC-1 and fluorescence-activated cell sorting analysis (Salvioli,
Ardizzoni et al. 1997), was evaluated for the possibility that Surv-T34A was stimulating
apoptosis by inducing depolarization within the mitochondria. Under normal circumstances, JC-1 accumulates in the inner mitochondrial membrane in which it oligomerizes
and fluoresces red. A reduction in Δψm results in diffusion of the dye from the mitochondria and a subsequent reduction in the mean red fluorescent intensity. As expected,
control HeLa cells showed a high mean red fluorescence (set to ~96%) after staining with
JC-1 (Figure 16). After treatment with staurosporine, we found that the mean red fluorescence of the mitochondria dropped rapidly within 6 h, indicating that the Δψm had
50
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Figure 16. Mitochondrial depolarization. The experimental conditions are the same as in
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quantifiable using flow cytometry. Staurosporine treatment for 6 h is used as a positive
control. Data are the mean±s.e. of two independent experiments.
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collapsed (Figure 16). HeLa cells treated with Surv-T34A, but not Surv-WT, showed a
time-dependent reduction in the mean red fluorescence intensity. However, in repeated
experiments this was always slower than that seen for staurosporine (Figure 16). This
may indicate that mitochondrial depolarisation due to Surv-T34A is a secondary event
and not the primary effect of Surv-T34A-induced killing or that mitochondrial depolarization is one of many factors involved in Surv-T34A-induced killing.

Effect of Surv-T34A and Surv-WT and UV Radiation
on Tumor Cell Apoptosis
Incubation of HeLa cells with UV radiation resulted in enhanced numbers of hypodiploid cells, which are sub-G1 DNA content or apoptotic cells (Figure 17A) by DNA
content analysis and flow cytometry. In comparison to control cells that were set at ~5%,
UV radiation treatment resulted in 35% of the cells exhibiting a sub-G1 DNA content.
However, cells grown for 24 hrs. in Surv-WT-CM before UV treatment were fully protected from the effects of the UV energy. In turn, Surv-T34A enhanced the killing effects
of the UV and resulted in 75% of the cells exhibiting a sub-G1 content (Figure 17A).

Effect of Surv-T34A and Surv-WT and Chemotherapeutic
Drugs on Tumor Cell Apoptosis
To establish that the effects recorded in HeLa cells were not specific for this cell line
alone or for UV radiation, we selected human pancreatic adenocarcinoma (Capan1 and
Capan2) cell lines to study drug sensitivity and responsiveness in the presence or absence
of Surv-WT- and Surv-T34A-CM. Effects of taxol, 5-FU, Ad, and CDPD were studied.
Capan1 cells exhibited an enhanced susceptibility to taxol, 5-FU, Ad, CDPD-induced cell
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death after the addition of Surv-T34A-CM, whereas Surv-WT-CM-incubated cells were
protected from taxol, 5-FU, and CDPD-induced cytotoxicity (Figure 17B). Only a modest
protection was recorded against Ad. Interestingly, Surv-WT-CM treatment protected Capan2 cells from the cytotoxic effects of 5-FU and again only a modest protection was
recorded against taxol, Ad, and CDPD. Treatment of Capan2 cells with Surv-T34A-CM
was as effective as taxol, more effective than CDPD and 5-FU and less effective as Ad
alone. Surv-T34A when combined with taxol showed an additional cytotoxicity that may
be quantitatively additive at best. When combined with CDPD, Surv-T34A did not provide further enhancement to the killing effects over that of Surv-T34A alone, which was
substantial, and when paired with 5-FU or Ad, the individual cytotoxic effects of SurvT34A were reduced (Figure 17C).

Survivin Containing CM Induces Cancer Cell Invasion in vitro
To determine the function of secreted Survivin in regulating cancer cell invasion
through collagen, we plated HeLa cells on collagen-coated inserts in the presence of control, Surv-WT-, or Surv-T34A-CM. Cells were grown for 24 h, dissociated, lysed, and
then evaluated for invasion by measuring the fluorescence emission (CyQuant GR dye).
HeLa cells exhibited an average fourfold increase in cell invasion when grown with SurvWT-CM in the lower chamber as compared to control medium (Figure 18). Surv-T34ACM invasion levels were little changed from that of the control as were those cells that
were treated with medium that had been depleted of Survivin.
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apoptotic cells serves as an immunoregulatory event that helps
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Discussion
The growth and spread of cancer depends as much on the host response to the tumor as
on the biological characteristics of the tumor itself. The IAP Survivin has been shown
aberrantly expressed in cancer but undetectable in normal differentiated adult tissue. It
has been implicated in both control of apoptosis (Ambrosini, Adida et al. 1997, Adida,
Crotty et al. 1998)and regulation of cell division (Deveraux and Reed 1999, Li,
Ackermann et al. 1999, Gianani, Jarboe et al. 2001). . Indeed, Survivin expression has
been shown to be cell cycle regulated with its highest expression in G2/M phase, and it
has been shown that much of its function comes from its subcellular localization with residences in the cytosol, nucleus, and mitochondria (Li, Ackermann et al. 1999, Li 2003).
Recent reports on patients with rheumatoid arthritis have described a new Survivin localization and the possibility that it may also function in the extracellular space (Bokarewa,
Lindblad et al. 2005, Mera, Magnusson et al. 2008). Moreover, in these patients, extracellular Survivin was directly linked to an erosive course of joint disease and its origin was
prescribed to peripheral blood leukocytes where its expression is constitutive. Furthermore, Survivin was shown to bind extracellularly to neutrophils inducing the p38MAPK-dependent expression of α- and β-integrins (Mera, Magnusson et al. 2008). Taken
together, the finding of a new and physiologically functional pool of Survivin provides
new insight into the function of IAPs as well as other relevant tumor-associated proteins
in the tumor microenvironment.
In this study we have shown that an extracellular form of Survivin is detectable in
CM taken from cancer cells. We also demonstrate that unlike Survivin from the rheumatoid arthritis study, Survivin from cancer cells is readily taken up by cancer cells rather
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maintain tolerance whereas necrotic cells evoke an inflammatory
cascade that mobilises effector responses. On the basis of our
findings, we postulate that many59of these released cancer antigens
could in addition to modulating immune function prime the cells
within the tumour microenvironment for the phenotypes associated with tumour invasion and metastasis that are listed above.
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than binding only to their surface (Mera, Magnusson et al. 2008). Finally, upon incubation in medium containing this extracellular pool of Survivin, cancer cells responded
physiologically, becoming more resistant to therapy, proliferating more rapidly, and having an increased metastatic potential. These findings lead us to believe that extracellular
Survivin may modulate, in vivo, the tumor microenvironment for the purpose of tumor
evolution and these findings in part may be responsible for the observations that patients
with a high expression of Survivin protein display advanced disease, high-grade disease,
abbreviated survival, resistance to therapy, and accelerated tumor recurrences (Andersen,
Svane et al. 2007).
We have also shown that stable cells expressing the previously described (Mesri,
Wall et al. 2001, O'Connor, Wall et al. 2002) pro-apoptotic Survivin mutant Thr34 →
Ala (Surv-T34A) release a form of Survivin that is able to disrupt the cell cycle and cause
a caspase-dependent, mitochondrial depolarization-associated apoptosis. When combined
with UV radiation or with the chemotherapeutic agents taxol, Ad, CDPD, or 5-FU, SurvT34As pro-apoptotic ability was amplified. It was not surprising that these modalities
were differentially enhanced or inhibited by Surv-T34A or Surv-WT because they have
varied mechanisms of action. Surv-T34A was found to be as effective in enhancing therapy-induced cell killing as Surv-WT was in protecting against therapy-induced cell
killing. These differential effects seemed not to follow the p53 status of the cell lines tested as Surv-WT was as effective at protecting those cells lacking the tumor suppressor and
transcription factor as it was for those cells positive for p53. It has been shown that Survivin gene transcription is repressed by WT p53 (Li 2003)but little is known of p53's
ability to modify the protein's function. A more careful evaluation of this finding is re-
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quired.
The precise mechanism by which this Survivin mutant causes apoptosis is still incompletely understood. The mutations that allowed for the generation of stable cells as
well as their ability to induce apoptosis through the caspase-2- and caspase-9-dependent
pathways are currently being evaluated in our laboratory. Importantly, a quantifiable
highly stable extracellular form of Survivin has been identified. This novel T34A Survivin molecule is readily taken up by cancer cells after which characteristics of apoptotic
cell death are measurable. Further, it potentiates the killing effects of other cancer therapeutics. It is our belief that this extracellular Surv-T34A molecule has significant
potential as a novel therapeutic or as part of a novel therapeutic and possible immunotherapy regimen.
Tumor invasion and metastasis are very complex processes that are yet very poorly understood but account for 90% of all human cancer deaths (Sporn 1996, Hanahan and
Weinberg 2000). The mechanism involves coupling and uncoupling of cells to their microenvironment, activation of extracellular proteases, and modulation in tethering
proteins such as cadherins, β-catenin, and integrins (Hanahan and Weinberg 2000). As
Survivin has already been shown to modulate the integrin proteins CD49d, CD11b, and
CD11c on leukocytes (Mera, Magnusson et al. 2008), we hypothesized that it may also
modulate the invasive capabilities of cancer cells. In our hands Surv-WT-CM stimulated
a 3- to 4-fold increase in collagen invasion in comparison with the control medium alone
or medium containing Surv-T34A. Medium depleted of Survivin using antibodies first
that recognized the fusion proteins Flag and HA and then one and three rounds of antiSurvivin antibody depletion, completely inhibited Survivin-induced collagen invasion
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thus placing Survivin as a central player in this increased metastatic potential.
Stress-induced cancer cell death by means of apoptosis, necrosis, and autophagy
occurs continually during tumor development and progression (Fonseca and Dranoff
2008). What the ramifications of this to the tumor microenvironment is only beginning to
be evaluated. It is believed that the capture of apoptotic cells serves as an immunoregulatory event that helps maintain tolerance whereas necrotic cells evoke an inflammatory
cascade that mobilizes effector responses. On the basis of our findings, we postulate that
many of these released cancer antigens could in addition to modulating immune function
prime the cells within the tumor microenvironment for the phenotypes associated with
tumor invasion and metastasis that are listed above.
Survivin expression in CM was measured extracellularly using ELISA. It is not
known whether extracellular Survivin originates from dead cells or is the subject of active secretion. Comparing Survivin quantity from 1 to 10% lysates to that of CM argues
for active secretion rather than necrosis as SaOS2, Capan1, and HeLa-S-Surv-WT cells
all have equal or more Survivin protein but yet have no dead or dying cells as determined
visually and by Trypan blue exclusion. Importantly, Survivin found extracellularly creates a more erosive disease in patients with rheumatoid arthritis (Bokarewa, Lindblad et
al. 2005) and in our cancer cell culture models, parameters that are considered clinically
unfavorable in cancer patients: proliferative advantage, enhanced resistance to therapy,
and enhanced metastatic potential. Investigating recombinant Survivin's ability to recapitulate the effects recorded using CM-containing Survivin proved unprofitable. From
these experiments, we conclude that the Survivin recombinant protein, which has been
severed from its GST handle, is unable to induce similar phenotypes as the CM-
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containing Survivin as it is unable to enter the cancer cells. Further studies using circular
dichroism mass spectrometry will be required to compare these two forms of Survivin to
define differences in structure and or posttranslational modifications that may aid Survivin in binding with its yet to be defined receptor or trafficking proteins.
A deeper understanding of the mechanisms underlying this extracellular pool of
Survivin, the possible ramifications for tumorigenesis, and the possibility of exploiting it
for therapy are only a few of the many properties of this most fascinating of proteins that
we are continuing to evaluate.
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Abstract
Background
Current therapeutic options for advanced pancreatic cancer have been largely disappointing with modest results at best, and though adjuvant therapy remains
controversial, most remain in agreement that Gemcitabine should stand as part of any
combination study. The inhibitor of apoptosis (IAP) protein Survivin is a key factor in
maintaining apoptosis resistance, and its dominant-negative mutant (Survivin-T34A) has
been shown to block Survivin, inducing caspase activation and apoptosis.

Methods
In this study, exosomes, collected from a melanoma cell line built to harbor a tetracycline-regulated Survivin-T34A, were plated on the pancreatic adenocarcinoma (MIA
PaCa-2) cell line. Evaluation of the presence of Survivin-T34A in these exosomes followed by their ability to induce Gemcitabine-potentiative cell killing was the objective of
this work.

Results
Here we show that exosomes collected in the absence of tetracycline (tet-off)
from the engineered melanoma cell do contain Survivin-T34A and when used alone or in
combination with Gemcitabine, induced a significant increase in apoptotic cell death
when compared to Gemcitabine alone on a variety of pancreatic cancer cell lines.
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Conclusion
This exosomes/Survivin-T34A study shows that a new delivery method for anticancer proteins within the cancer microenvironment may prove useful in targeting
cancers of the pancreas.

Keywords: Survivin, Survivin-T34A, exosomes, pancreatic cancer, Gemcitabine
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death in the United States,
with an average 5-year survival rate of 5% for all stages of the disease (Kleeff, Michalski
et al. 2006). Pancreatic cancer has an annual mortality rate of approximately 95% with
over 250,000 patients dying worldwide (Jemal, Bray et al. 2011). Pancreatic cancer exhibits no clear early warning signs or symptoms and it is often detected after it is too late
for pancreatic resection. Currently, if diagnosed at early stages, surgical resection remains
the most efficacious treatment and offers the best patient outcome. However, only 20% of
pancreatic cancer patients meet these criteria (Muller, Friess et al. 2008). There is a need
to discover and implement new therapies or therapeutic combinations that increase the
survival rate of those afflicted with this pancreatic cancer. Gemcitabine remains the goldstandard for chemotherapy (Ueno, Kiyosawa et al. 2007). However, while Gemcitabine
has shown significant benefit in clinical applications, its ability to effectively impact pancreatic cancer is limited. Currently, combinatory treatments using Gemcitabine and other
therapeutics have shown no significant improvements in survival rates (Oettle and
Neuhaus 2007, Reni, Cereda et al. 2007, Galloway, Aspe et al. 2009). However, the cancer research field is moving rapidly towards combinatorial therapies including combined
multiple chemotherapy drugs (Vishnu, Colon-Otero et al. 2012), radiation with chemotherapy (Galloway, Aspe et al. 2009), and virotherapy with chemotherapy
(Karapanagiotou, Roulstone et al. 2012). The IAP Survivin seems to be one of the key
players in resistance to many of these cancer therapies (Asanuma, Kobayashi et al. 2002,
Li 2003, Kami, Doi et al. 2005) and therefore a strategy to inhibit its action, when combined with standard treatment options may prove beneficial.
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Survivin is a possible prognostic marker for pancreatic cancer patients (Satoh,
Kaneko et al. 2001, Sarela, Verbeke et al. 2002, Kami, Doi et al. 2004). Though expressed in most human cancers and present during embryonic and fetal development
(Adida, Crotty et al. 1998), its aberrantly high protein expression in cancer cells and low
level of expression in most normal tissues makes Survivin an important anticancer target
(Fukuda and Pelus 2006). Survivin overexpression in cancer has been described as a predictive factor in determining response to chemotherapy and radiotherapy (Galloway,
Aspe et al. 2009, Zhu, Wang et al. 2011, Shen, Zheng et al. 2012). Survivin reduces cell
death induced by several anticancer agents including paclitaxel, etoposide and tumor necrosis factor alpha. Conversely, inhibition of Survivin reduces tumor growth potential
and sensitizes tumor cells to many of the same chemotherapeutic agents (Mita, Mita et al.
2008).
We have reported a marked enhancement of Survivin’s role in therapeutic resistance to both chemo- and radiotherapy in pancreatic cancer (Galloway, Aspe et al.
2009). Reduction of Survivin levels and/or inhibition of the protein’s anti-apoptotic properties may assist in making cancer cells more susceptible to existing (and future)
therapeutic regimens. Successful strategies against intracellular Survivin include molecular antagonists such as antisense oligos, RNA inhibition, Survivin-specific cytolytic T
cells, the nonphosphorylatable dominant negative Survivin mutant Thr34→ Ala (T34A),
and most recently, binding interface mimetics (Olie, Simoes-Wust et al. 2000, Andersen,
Pedersen et al. 2001, Grossman, Kim et al. 2001, Kanwar, Shen et al. 2001, Mesri, Wall
et al. 2001, Wall, O'Connor et al. 2003, Plescia, Salz et al. 2005, Andersen, Svane et al.
2007).

68

The loss of phosphorylation at the Survivin Thr34 site is significant as it results in
the dissociation of the caspase-9/Survivin protein complex, leading to antitumor effects
(Grossman, Kim et al. 2001, Peng, Yang et al. 2008, Li, Zhao et al. 2009, Shen, Liu et al.
2009, Aspe and Wall 2010). Mesri, et al. employed Survivin-T34A treatment in vivo via
adenoviral vectors, with their results yielding only modest levels of success (Mesri, Wall
et al. 2001). A better delivery method will need to be utilized if this Survivin inhibitor is
to prove efficacious in vivo.
Conditioned media (CM) collected from cervical, pancreatic, prostate, breast cancer, osteosarcomas, leukemia cell lines (Khan, Aspe et al. 2009) and CM collected from a
Survivin-T34A overexpressing HeLa cell line provided evidence that functional Survivin
can be found extracellularly in the CM. We have recently shown extracellular Survivin to
reside in small 50-100 nm vesicles called exosomes (Khan, Jutzy et al. 2011). Exosomes
have been described as a pivotal mechanism in the multicellular organism for cell to cell
communication as they allow for cells to exchange information through transferal of soluable factors such as proteins, RNAs and miRNA (Bobrie and Thery 2013). More
recently, exosomes have been exploited for cancer immunotherapy as there may be opportunity to adapt them as drug delivery vehicles for therapeutic intervention(S, Mager et
al. 2013). The typical exosome is 50-100 nm in size and originates intracellularly, displaying MHC class I and class II, heat shock proteins, tetraspanin proteins and in our
hands inhibitor of apoptosis (IAP) proteins (Tan, De La Pena et al. 2010, Khan, Jutzy et
al. 2011).
We showed in this undertaking Survivin-T34A CM eliciting anticancer effects
such as induced apoptosis with loss of mitochondrial potential. The goal of the present
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study was to determine if the cells engineered to overexpress the Survivin-T34A dominant-negative mutant would produce a functional, exosomally packaged, Survivin-T34A
which when used in combination with Gemcitabine might significantly enhance the death
of pancreatic cancer cells, in vitro.

Materials and Methods
Cell Cultures
Pancreatic adenocarcinoma (MIA PaCa-2) cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA) and maintained in DMEM,
supplemented with 100 units of penicillin, 100 g/mL streptomycin, 300 g of Lglutamine, 10% heat inactivated FBS (ATCC), and 2.5% horse serum. Exosomes were
isolated from YUSAC 2, a melanoma cell line obtained from Dr. Doug Grossman at the
Huntsman Cancer Institute in Salt Lake City, Utah. The two cell line derivatives from
YUSAC 2 were designed to overexpress either Survivin-WT (4C7 cells) or SurvivinT34A (F5C4 cells) in the absence of tetracycline (tet), otherwise only normal endogenous levels of Survivin are produced. YUSAC 2 cells were maintained in DMEM
(CellGro, Manassas, VA) supplemented with 100 units of penicillin, 100 g/mL streptomycin, 300 g of L-glutamine, 5% newborn calf serum (Thermo Scientific HyClone,
Rockford, IL), 0.5 g/mL tetracycline (tet-off system), 1.5 mg/mL Geneticin G418
(Teknova, Holister, CA), and 2 mM NaOH. YUSAC 2 cells were grown to 60% confluency in the presence of tetracycline in order to establish a healthy monolayer culture.
Subsequently, cells were washed carefully twice in PBS followed by the addition of media in the absence of tetracycline. All cells were grown at 37 °C in a humidified
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atmosphere containing 5% CO2.

Gemcitabine Treatment
Gemcitabine (Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO and added
to cells simultaneously with exosome treatment. Final DMSO concentration was 0.03%.
Final Gemcitabine concentration used was 10 μM. The cells were returned to the incubator and harvested after 24, 48, or 72 hrs. for apoptosis analysis by flow cytometry.

Exosome Isolation and Quantification
Exosomes were isolated from conditioned media (CM) as we have previously reported (Khan, Jutzy et al. 2011). In brief, the culture media was collected from cells in
culture after 24 hrs.. The CM was centrifuged at 10,000 × g for 10 min at 4 °C to pellet
the minor amounts of cells and cell debris. CM was filtered through 0.22 µm syringe followed by centrifugation at 100,000 × g for 18 hrs. at 4 °C on a 30% sucrose cushion
(Thery, Amigorena et al. 2006). The sucrose cushion containing exosomes was collected
and washed with PBS followed by additional centrifugation at 100,000 × g for 18 hrs. at
4 °C. Exosome pellets were collected and stored at -80 °C. Exosome quantification was
accomplished using acetylcholinesterase assay, according to the protocol of Lancaster
and Febbraio (Lancaster and Febbraio 2005). Briefly, acetylcholinesterase activity was
employed to determine the presence of exosome vesicles. 40 µL of the exosome fraction
was suspended in 110 µL of PBS. 37.5 µL of this PBS-diluted exosome fraction was then
added to individual wells on a 96-well flat bottom plate. 112.5 µL of 1.25 mM acetylthiocholine and 150 µL of 0.1 mM 5,5’-dithio-bis(2-nitrobenzoic acid) were added to PBS-
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diluted exosomes. The change in absorbance at 412 nm was monitored every 5 min for 30
min. The data presented represents acetylcholinesterase enzymatic activity after a 30 min
incubation. Exosome and whole cell lysate (WCL) protein was quantified using the BCA
assay on a µQuant microplate spectrophotometer (Bio-Tek, Winooski, VT) and analyzed
using KC Junior Software (Bio-Tek).

Apoptosis and Cell Cycle Analysis
Sub-confluent cultures of the pancreatic cancer cells were incubated with vehicle
(DMSO), Gemcitabine (0 to 500 M) and/or exposed to exosomes treatment (0-1500
g/mL total protein, exosomes were sterilized using 0.22µm syringe filter) for 0, 24, 48,
and 72 hrs. at 37°C. Cells were harvested, prepared, and analyzed for DNA content using
a Becton Dickinson FACScan flow cytometer (Becton Dickinson, San Jose, CA) as described previously (Li, Ackermann et al. 1999, Khan, Jutzy et al. 2011). The distribution
of cells in the different phases of the cell cycle was analyzed from DNA histograms using
BD CellQuest software (Becton Dickinson and Company, San Jose, CA).

Western Blot Analysis
Whole cell lysates (WCLs) were prepared as previously described (Galloway,
Aspe et al. 2009) and quantified as described above. Proteins (30 g) were separated using 12 or 15% Bis-Tris polyacrylamide gels and then transferred onto nitrocellulose
membranes (Bio-Rad) and probed using 1-5 g/ml of the following antibodies: rabbit
polyclonal anti-Survivin (Novus, Littleton, CO), rabbit anti-ppSurvivin-Thr34 (Novus),
rabbit polyclonal anti-β-actin (BioLegend, San Diego, CA), and mouse polyclonal anti72

LAMP-1 (Cell Signaling Technologies, Beverly, MA). Secondary antibodies (IR-Dyeconjugated) were goat anti-rabbit and goat anti-mouse immunoglobulin (LI-COR, Lincoln, Nebraska) used at a 1:5000 dilution. Membranes were blocked for 1 hr. using
blocking reagent purchased from LI-COR. Membranes were incubated overnight in primary antibody followed by three 15 minute PBS-Tween wash steps and a final 1 hour
secondary antibody incubation followed again by three 15 minute PBS-Tween washings.
Immunoreactive bands were detected using the Odyssey imaging system (LI-COR). βactin or LAMP-1 was used as Western blot loading controls for either cell lysates or exosomal protein, respectively.

Statistical Analysis
Multiple comparisons among different groups were calculated by using Multiple Analysis
of Variance (MANOVA) as we have done in the past (Khan, Jutzy et al. 2012). Student ttest (two-tailed) was used to evaluate the significance of changes between control groups
and experimental groups. Probability values P<0.05 were considered statistically significant.

Results
The Presence of Survivin-T34A Induces Time-dependent Apoptosis
The melanoma cell line, YUSAC 2, was engineered to overexpress WT Survivin
(4C7) or mutant T34A (F5C4), as previously reported (Grossman, Kim et al. 2001). The
YUSAC 2 cells were continuously treated with 0.5 µg/mL of tetracycline (tet) to prevent
overexpression of Survivin-WT (4C7 cells) or Survivin-T34A (F5C4 cells) in this tet-off
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system. Cells were harvested 6, 12, 18 and 24 hrs. after removal of tet for analysis by
Western blot and flow cytometry (Figure 19). Following tet removal, Survivin protein
was concomitantly increased in both cell lines in a time-dependent manner (Figure 19A)
as it has been previously reported (Grossman, Kim et al. 2001). Removal of tet from
F5C4 cells resulted in increased apoptosis in a time-dependent manner, maximizing at 72
hrs., while no increase in apoptosis was recorded in the 4C7 cells treated under the same
conditions (Figure 19B).

Survivin-T34A Overexpressing Cells Showed Decreased
Phosphorylated Survivin in a Timedependent Manner
4C7 and F5C4 cells were incubated in either the presence or absence of tet for 24
hrs., and levels of Survivin, phospho-Survivin and -actin were analyzed by Western
blotting. 4C7 and F5C4 cells expressed increased Survivin levels in the absence of tet
compared to tet-treated control cells (Figure 20). Survivin phosphorylation at Thr34 was
confirmed by Western blotting using a phospho-specific Survivin Thr34 antibody as has
been previously shown (Grossman, Kim et al. 2001). Tet-free F5C4 cells showed a decreased phospho-Survivin band compared to tet-free 4C7 cells.
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Figure 19. (A) Western blots of whole cell lysates of YUSAC 2 cell line derivatives. 4C7
or F5C4 cells were incubated in the presence or absence of tetracycline for 6, 12, 18, and
24 hrs., which in the absence of tetracycline will overexpress Survivin-WT or SurvivinT34A, respectively. Survivin is increased in a time-dependent manner when incubated in
the absence of tetracycline. Beta-actin was used as the loading control and molecular
weights (kDa) are shown on the left. Densitometry was undertaken to show the degree of
Survivin increase. (B) Histogram representing the percentage of apoptosis using propidium iodide (PI) analysis by flow cytometry, 4C7 show similar apoptosis levels for both
tet-treated and tet-free conditions. F5C4 cells have increasing apoptosis in a timedependent manner when incubated in tet-free media. Data are the mean ± SD of three independent experiments (*p<0.05).
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Figure 20. Western blot of whole cell lysates of YUSAC 2 cell line derivatives. 4C7 and
F5C4 cells were incubated in the presence or absence of tetracycline for 24 hrs., which in
the absence of tetracycline will overexpress wild-type or Survivin-T34A, respectively.
4C7 has increased Survivin in absence of tetracycline, which is concurrent with phosphorylated Survivin-Thr34. However, in the absence of tetracycline F5C4 also
overexpresses Survivin, but it is not phosphorylatable at the Thr34 site.
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YUSAC 2 Cells Release Survivin-containing Exosomes
In order to confirm that F5C4 cells release exosomes, we isolated exosomes by ultracentrifugation using a sucrose cushion as has been previously described (Thery,
Amigorena et al. 2006, Khan, Jutzy et al. 2011). Following ultracentrifugation, exosome
levels were analyzed using the acetylcholinesterase enzyme (AChE) activity assay (Figure 21A). No significant difference in exosome levels between tet-treated and tet-free
cells was measured at 24 hrs., signifying that the number of exosomes released is independent of the tet-system.
Exosomal Survivin content was evaluated by Western blotting. Survivin expression was elevated after tet removal in exosomes from both 4C7 and F5C4 cells (Figure
21B). This was similar to observed levels of Survivin expression in whole cell lysates
from YUSAC 2 cells. In order to evaluate Survivin-T34A presence in the exosomes released from F5C4 cells, we employed the phospho-specific Survivin Thr34 antibody for
Western blots of these exosomes. Survivin was increased in the exosomes from tet-free
F5C4 as was recorded in the immunoblots from the parent cells. However, there were no
phosphorylated-Survivin bands from either exosomes of tet-treated or tet-free F5C4 cells
(Figure 21C). The presence of tet-removal-enhanced Survivin, coupled with the absence
of phosphorylated-Survivin, provides strong evidence that these exosomes contain the
dominant-negative Survivin-T34A.
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Figure 21. (A) Histogram representing an acetylcholinesterase enzyme activity assay to
quantify exosome numbers relative to fresh complete media. Exosomes are present as
represented by the graph when compared to control. There is no difference within the
same cells when treated with tetracycline or without. Data are the mean ± SD of 3 independent experiments. (B) Both YUSAC 2-derived cell lines overexpress Survivin in the
absence of tetracycline. (C) Western blots of proteins isolated from exosomes collected
from F5C4 cells after incubation in the presence or absence of tetracycline for 24 hrs..
LAMP-1 was used as the loading control with molecular weights (kDa) shown on the
left.
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Exosomes Containing Survivin-T34A Induce Apoptosis in
MIA PaCa-2 Pancreatic Cancer Cells
Exosomes isolated from tet-treated F5C4 (endogenous WT Survivin) cells were
employed as the control for exosomes isolated from tet-free F5C4 cells (Survivin-T34A).
There was no significant apoptotic induction (≤10%) after MIA PaCa 2 cells were treated
with 200, 1000 or 2000 µg/mL of exosomes purified from tet-treated F5C4 cells after 24
and 48 hrs. (Figure 22). MIA PaCa 2 cells were then treated using exosomes containing
Survivin-T34A (150 and 750 µg/mL based on total exosomal protein). Results showed
little apoptosis (~5%) versus treatment by control exosomes (from tet-treated F5C4 cells)
at 24 hrs. (Figure 22). However, using Survivin-T34A exosomes (1500 µg/mL), a marked
48 hrs. increase in apoptosis (30.5%) was measured.

Survivin-T34A Exosomes Enhance Gemcitabine Treatment
on Pancreatic Cancer Cells
In order to investigate whether exosomes containing Survivin-T34A could enhance Gemcitabine-cytotoxicity, MIA PaCa 2 cells were treated with either exosomes
containing Survivin-WT (200 µg/mL) or Survivin-T34A (150 µg/mL) or 10 µM Gemcitabine. Gemcitabine dosage levels conformed to the protocols previously established in
our laboratory (Galloway, Aspe et al. 2009). Exosome concentrations were chosen that
did not induce a measurable level of apoptosis (Figure 22) at 24 and 48 hrs. as an induced
additive or potentiative response from the combination was the goal. We also measured
apoptotic cell death after pancreatic cancer cells were treated with a combination of exosomes and Gemcitabine. At 24 hrs., no marked differences
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Figure 22. Histograms representing the percent apoptosis in MIA PaCa2 cells following
exosome treatment for 24 and 48 hrs.. MIA PaCa 2 cells treated for 24 hrs. showed little
to no increase in apoptosis after exosomes treatment. After 48 hrs. treatment, only 1500
g/mL of exosomes containing Survivin-T34A induced apoptosis (30.5%). Percent apoptosis was determined from sub-G1 DNA content analyzing propidium iodide staining by
flow cytometry. Data are the mean ± SD of 2 independent experiments.
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Figure 23. MIA PaCa 2 cells were treated with either 10 M Gemcitabine, 150 or 200
g/mL (total exosomal protein from F5C4), or the combination of both. MIA PaCa 2
cells treated for 24 hrs. showed little to no marked increase in apoptosis (<5%) after exosomes treatment. 10 M Gemcitabine had modest apoptosis induction over control
(~11% vs. 2%, respectively). The combination of 10 M Gemcitabine with 150 g/mL
exosomes containing Survivin-T34A yielded 32% apoptosis (~30% greater than control)
after 48 hrs. Percent apoptosis was determined from sub-G1 DNA content analyzing propidium iodide staining by flow cytometry. Data are the mean ± SD of 2 independent
experiments (*p<0.05, **p<0.01).
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between the various treatments (24 hrs., <4%) were recorded (Figure 23). As expected
Gemcitabine induced modest apoptosis vs. control (10% and 2%, respectively) after 48
hrs.. However, the combination of exosomes containing Survivin-T34A with 10 µM
Gemcitabine treatment displayed the greatest enhanced apoptosis compared to control
and the single modality treatments (32% apoptosis vs. less than 10% apoptosis) after 48
hrs.. The combination treatment utilizing exosomes containing Survivin-T34A yielded
the same levels of apoptosis as did treatment using 1500 µg/mL Survivin-T34A exosomes.

Discussion
We have previously described Survivin’s (WT and T34A) presence in the extracellular conditioned media (Bokarewa, Lindblad et al. 2005, Mera, Magnusson et al.
2008, Khan, Aspe et al. 2009, Khan, Jutzy et al. 2011), and that extracellular Survivin can
be taken up by cancer cells resulting in functional effects such as proliferation, invasion
and resistance (Khan, Aspe et al. 2009). We have also shown that Survivin is released via
small membrane-bound vesicles called exosomes (Khan, Jutzy et al. 2011). Building upon these findings, we have sought to test whether or not exosomes containing the
apoptosis-inducing Survivin mutant, T34A, could be produced and if so, used either
alone or in combination with other treatment methods as a cancer therapeutic.
To this end, the YUSAC 2 tet-off system (Grossman, Kim et al. 2001) was employed. Exosomes must be collected early so that the vesicles being harvested are intact
and functional with the production of apoptotic bodies kept at a minimum. The F5C4 cell
lines provide a good system in which the tet-off regulatory mechanisms allow for Sur-
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vivin-T34A to be controlled systematically in all cells. The released quantity of exosomes
was independent of the tet-system, which is important because any changes in protein
levels within the exosomes are the result of the tet-system and not the quantity of exosomes. Our results demonstrate for the first time that Survivin-T34A is released from the
cells via exosomes.
Utilizing exosomes for anticancer therapy an emerging and rapidly growing field
(Khan, Jutzy et al. 2011). Dendritic exosomes (DEX) are the most commonly utilized exosomes for such therapy (Zitvogel, Regnault et al. 1998, Wolfers, Lozier et al. 2001,
Couzin 2005, Chaput, Flament et al. 2006, Tan, De La Pena et al. 2010). However, DEXs
are typically used as a form of immunotherapy – a way to prime the immune system
against tumor cells (Khan, Jutzy et al. 2011). Our aim in this study was to directly attack
tumor cells with exosomes containing Survivin-T34A.
MIA PaCa 2 cells treated in culture with exosomes containing Survivin-T34A undergo enhanced apoptosis. When we compared Survivin-T34A exosome-induced
apoptosis levels to that induced by Gemcitabine alone, 100 µM Gemcitabine yielded 50%
less apoptosis in the pancreatic cancer cell lines PANC1 and MIA PaCa-2 (Galloway,
Aspe et al. 2009) then did 1500 g/mL of Survivin-T34A-containing exosomes on the
same cell lines. We could not obtain similar levels of apoptosis as exosomal SurvivinT34A using our highest concentration of Gemcitabine (500 µM, data not shown). We
therefore combined low doses of exosomal Survivin-T34A (150 µg/mL total protein)
with Gemcitabine (10 µM) to investigate whether Survivin-T34A could enhance Gemcitabine’s cytotoxic effects. Alone, these doses did not yield an increase in apoptosis over
control. However, there was a marked enhancement of apoptosis when Survivin-T34A
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exosomes and Gemcitabine were combined. Using 150 µg/mL of Survivin-T34A exosomes and 10 µM Gemcitabine, apoptosis levels reached greater than 30% after 48 hrs. of
combined treatment. We believe the enhancement from the combination treatments occurred because of the mechanism of Gemcitabine. Gemcitabine has been shown to reduce
G2/M cell cycle arrest which reduces cellular Survivin levels (Aspe and Wall 2010). We
also have found that a modest amount of stress induces wild-type Survivin in this model
system (data not shown). This combined with Survivin-T34A exosomes, which target
Survivin, enhances apoptosis with much lower dosages because it is believed that Survivin-T34A targets and disrupts Survivin-associated protection of the cancer cell (BlancBrude, Mesri et al. 2003, Liu, Brouha et al. 2004, Aspe and Wall 2010).
In summary, delivery has been the confounding factor for using the novel Survivin-T34A as an effective therapeutic. This study not only adds to the importance of
using Survivin-T34A as a cancer therapeutic for the treatment of pancreatic cancer, but
that exosome delivery may provide a potential mechanism for effective tumor delivery.
Cancer research and therapy have been rapidly moving towards combinatorial therapies
but clinically, Gemcitabine remains the most prominent player in effective pancreatic
cancer therapy. In closing we would like to emphasize the importance of continued exploration of the potential of combining exosome delivery of Survivin-T34A with
Gemcitabine and other anticancer therapeutic regimens. These studies may prove relevance for the discovery and implementation of novel pancreatic cancer therapeutic
strategies to improve the efficacy of chemotherapy-induced apoptosis in patients
(Nicholson 2000).
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CHAPTER FOUR
CONCLUSION
Our finding that Survivin, a unique human inhibitor of apoptosis (IAP), has intercellular transport and signaling capabilities via exosomes is a significant and potentially
seminal discovery. This led to another significant, potential discovery of Survivin-T34A
being packaged into exosomes from genetically engineered YUSAC-2 cells which overexpress Survivin-T34A via a tet-off system. Consistent with Survivin’s association with
unfavorable clinicopathological parameters, trafficking Survivin throughout the tumor
microenvironment can drive the aggressive status of the tumor prohibiting or minimizing
therapeutic results. Thus, treatment of a tumor using Survivin-T34A induces apoptosis
and sensitizes Gemcitabine induced cell death in MIA PaCA 2 cells. With the new discovery that exosomes containing Survivin-T34A, taken from cells that overexpress
Survivin-T34A, is able to kill cancer cells in vitro, we hope to further enhance the scientific data banks and pave new paths for clinical modalities and regimens. Thus, the
outcomes of this research project is significant to both cancer biology and clinical cancer
research as a potentially novel cancer treatment. The knowledge that will make this possible includes: the elucidation of T34A target cell populations, cell-surface receptors,
changes that occur in the target tissue at the molecular and cellular level, the mechanism
of therapeutic action, and its site of action. Other potential future studies have also been
described in Appendix A of this dissertation.
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APPENDIX A
FUTURE STUDIES
Part 1:

To characterize the combinatorial therapy of exosomes with Gemcitabine in vivo to induce apoptosis and increase animal survival rates.

Rationale
Based on the project in this document, proof of concept in vitro has shown the potential for enhancing the “Gold Standard” (Gemcitabine) for pancreatic cancer. Proof of
concept in vivo is the next step. Because of the current poor prognosis for all pancreatic
cancer patients, great strides to advance treatment of pancreatic cancer is essential. The
novelty of this study is the delivery of exosomal based Survivin-T34A which may enhance Gemecitabine treatment while reducing toxicity. The objective of this study is to
show proof of concept that exosomal Survivin-T34A enhances Gemcitabine treatment in mice. To accomplish this project, SCID mice will be injected orthotopically into
the pancreas with MIA PaCa 2 cells. Once the tumor has been established, treatment with
exosomes and Gemcitabine will follow. Then, apoptosis, tumor size, and animal survival
rates will be characterized.

Part 2:

To characterize the mechanism by which Survivin-T34A causes release
of Cytochrome c from the mitochondria inducing the intrinsic pathway
of apoptosis as well as the possibility that Survivin through physical as99

sociation with players within the intrinsic apoptotic pathway, inhibits or
mediates this phenomenon.
Rationale
Proof of concept in vitro has revealed promising results, a logical next step is
proof of mechanism. Currently, the intrinsic pathway of apoptosis involves Cytochrome
c, which is known to be released from the mitochondria as well as other proapoptotic proteins into the cytosol. Cytochrome c and cleaved Caspase-9 then bind to Apaf-1 to form
the apoptosome therefore promoting caspase activation, PARP cleavage, and cell death.
Phosphorylated Survivin-Thr34 is believed to the mechanism by which Cytochrome c is
released into the cytosol is still unknown. Initially, Cytochrome c was thought to be released through mitochondrial membrane depolarization and mitochondrial permeability
transition (MPT) - the result of the permeability transition pore (PTP). The PTP in the
inner membrane opens and causes swelling of the matrix space, thus causing the outer
membrane to rupture and spill Cytochrome c and other proapoptotic proteins into the cytosol. Recent studies using cyclophilin D knockouts have shown that PTP is primarily
involved in necrosis and ischemia-reperfusion injury and less likely in intrinsic apoptosis
and that Cytochrome c can be released in the absence of mitochondrial membrane depolarization. Instead, the mitochondrial apoptosis induced channel (MAC) has been
proposed as the alternative mechanism by which Cytochrome c is released into the cytosol. Following Cytochrome c release, Survivin has been speculated to directly inhibit
caspases. Although several groups have reported that Survivin does not bind directly to
Caspase-3, one group has shown a Survivin direct inhibition of both Caspase-3 and
Caspase-7 through physical chemistry techniques. Only one study has reported that phos100

phorylated Survivin-Thr34 can form a complex with Caspase-9 at midbodies and concomitantly inhibits apoptosis at cell division. From this we believe that Survivin physically
associates with the apoptosome and directly inhibits cleaved Caspase-3 within the complex. The objective of this study is to define the mechanism by which the
phosphorylation status of Survivin-Thr34 inhibits or induces Cytochrome c release
and its sequentially affected caspases. To accomplish this project, the use both 4C7 and
F5C4 cell lines will be utilized to compare and contrast the subcellular localization of
WT-Survivin and Survivin-T34A and their association with key mitochondrial factors.
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